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1.1. Novel drug delivery system (Shoba Rani., 2008) 
Recently, several technical advancements have resulted in the development of new 
techniques for drug delivery. These techniques are capable of controlling the rate of drug 
delivery, sustaining the duration of therapeutic activity and or targeting the delivery of 
drug to a tissue. These are referred to as novel drug delivery systems. And they have 
revolutionized the method of medication, provides a number of therapeutic benefits. 
The method by which a drug is delivered can have a significant effect on its efficacy. 
Some drugs have an optimum concentration range within which maximum benefit is 
derived, and concentrations above or below this range can be toxic or produce no 
therapeutic benefit at all. From this, new ideas on controlling the pharmacokinetics, 
pharmacodynamics, non-specific toxicity, immunogenicity, biorecognition, and efficacy 
of drugs were generated. These new strategies, often called drug delivery systems (DDS), 
are based on interdisciplinary approaches that combine polymer science, pharmaceutics, 
bioconjugate chemistry, and molecular biology. 
Controlled drug release and subsequent biodegradation are important for developing 
successful formulations. Potential release mechanisms involve. 
• Desorption of surface-bound /adsorbed drugs;  
• Diffusion through the carrier matrix;  
• Diffusion (in the case of nanocapsules) through the carrier wall;  
• Carrier matrix erosion. 
• A combined erosion /diffusion process.  
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 Advantages of novel drug delivery systems.(Illinois., 2004) 
• Improve therapy by increasing the duration of action and reducing side effects. 
• Increase patient compliance through decreased dosing frequency and 
convenient routes of administration 
• Achieved targeting of to a specific site to reduce unwanted side effects and 
obtain maximum efficacy. 
• Lead to reduction in dose and thus reduction side effects of drugs.  
• Decreased toxicity/side effects and increased convenience. 
• Shorter hospitalization and better patient compliance. 
• Viable treatments for previously in arable disease. 
• Potential prophylactic application 
The mode of delivery can be the difference between a drug’s success and failure, as 
the choice of a drug is often influenced by the way the medicine is administered. Sustained 
(or continuous) release of a drug involves polymers that release the drug at a controlled rate 
due to diffusion. It is achieved by using drug-carrying polymers that respond to specific 
stimuli (e.g., exposure to light, changes in pH or temperature).  
Novel drug delivery system is a system that offers multiple drug delivery solutions 
such as. 
 Oral Drug Delivery Systems and Materials  
 Parenteral and Implant Drug Delivery Systems  
 Pulmonary and Nasal Drug Delivery  
 Transmucosal Drug Delivery  
 Transdermal and Topical Drug Delivery  
 Delivery of Proteins and Peptides  
 Drug Delivery Pipelines  
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Nanoparticles for drug delivery. 
 Metal-based nanoparticles  
 Lipid-based nanoparticles  
 Polymer-based nanoparticles  
 Biological nanoparticles  
1.1.3. Methods of drug delivery.(ChayaVenkat., et al., 2003)  
 
Figure 1.1: Methods of drug delivery 
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 Types of novel drug delivery systems.( Costas Kaparissides., et al., 2005) 
• Hydrogels 
• Colloids 
• Microspores 
• Liposomes 
• Nanoparticles 
• Mucoadhesives 
• Transdermal 
Hydrogels. 
Hydrogels are three-dimensional, hydrophilic, polymeric networks capable of 
imbibing large amounts of water or biological fluids. The networks are composed of 
homopolymers or copolymers, and are insoluble due to the presence of chemical crosslinks 
(tie-points, junctions), or physical crosslinks, such as entanglements or crystallites. They are 
used to regulate drug release in reservoir-based, controlled release systems or as carriers in 
swellable and swelling-controlled release devices.    
Liposomes. 
Liposomes are a form of vesicles that consist either of many, few or just one 
phospholipid bilayers. The polar character of the liposomal core enables polar drug molecules 
to be encapsulated. Amphiphilic and lipophilic molecules are solubilized within the 
phospholipid bilayer according to their affinity towards the phospholipids. 
Nanoparticles. 
Nanoparticles(including nanospores and nanocapsules of size 10-200 nm) can adsorb 
or encapsulated a drug,thus protecting it from chemical & enzymatic degradation. 
Nanoparticles as drug carriers can be formed from both biodegradable and non- 
biodegradable polymer. 
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Drug delivery carriers. 
Colloidal drug carrier systems such as micellar solutions, vesicle and liquid crystal 
dispersions, as well as nanoparticle dispersions consisting of small particles of 10–400 nm. 
 
Figure 1.2: Pharmaceutical carriers 
1.2. Nanotechnology. (Shoba Rani., 2008) 
Definition of Nanoparticles. 
Nanoparticles are solid, colloidal particles ranging 10-1000nm (1µm) in size. They 
consist of macromolecular materials in which the active ingredient (drug or biologically 
active material) is dissolved, entrapped or encapsulated, and or absorbed or attached.  
Nanoparticles are often defined as particles of less than 100nm in diameter. 
Nanoparticles can be also defined as particles less than 100nm in diameter that exhibit new or 
enhanced size-dependent properties compared with larger particles of the same material. 
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 Images of Nanoparticle 
 
Figure 1.3: Images of Nanoparticle 
How Nanoparticles are transported into cells (Krishnadasan., et al.,2004)  
Nanoparticles, proteins and other macromolecules are taken up in the body's cells via 
various mechanisms. The nanoparticles are first encapsulated in fatty bubbles, called vesicles, 
which form on the cell surface. 
•Nanoparticle
400 × 355 - 59k -
jpg
•gold nanoparticles
320 × 320 - 41k -jpg
•Magnetic  
nanoparticles
813 × 611 - 88k - jpg
White light 
nanoparticles
400 × 300 - 195k - jpg
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Figure 1.4:Mechanism 
These vesicles merge with larger vesicles known as sorting endosomes, which can 
then mature into multivesicular bodies (MVBs). These MVBs, in turn, merge with lysosomes, 
where proteins and other macromolecules are broken down by proteases and other enzymes. 
Nanoparticles can be transported out of the cell via either sorting endosomes or recycling 
endosomes. 
Milestones of Nanoparticles.(Steffen Petersen., 2008) 
 30BC-640AD - The Lycurgus Cup (an apparently accidental early use of nanotech) 
contains gold and silver nanoparticles which cause it to change color from green to red when 
illuminated from the outside or inside, respectively. 
1450-1600 - Renaissance Artisans (Deruta Ceramicists) used copper and silver 
nanoparticles between 5 and 100 nm to produce metallic and iridescent glazes on ceramics. 
1827 - Photography depends upon light sensitive nanoparticles to form photographic images.  
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1856 - Researcher, Michael Faraday discovers/prepares the first metallic colloids. His gold 
colloids (fine particles suspended in solution) had unique optical/electronic properties. 
1959 - Richard Feynman delivers famous speech, "There's Plenty of Room at the Bottom" 
1960 - William McLellan constructs the first 250 microgram, 2000 rpm motor out of 13 
individual parts, as large as the period at the end of this sentence.  
1974 - Professor Norio Taniguchi becomes the first to formulate and use the term Nano-
technology. 
1985 - Fullerenes (commonly called buckyballs) are discovered by researchers at Rice 
University.  
1986 - Gerd Binnig, Christopher Gerber and Calvin F. Quate invent the Atomic Force 
Microscope 
1986 - Eric Drexler, an American Engineer and the founder of Foresight Nanotech Institute, 
writes Engines of Creation, introducing nanotechnology to the world.  
1989 - The first commercially available Atomic Force Microscope is introduced.  
1991 - Carbon nanotubes (CNT) are discovered by SumioIijima. Nanotubes are essentially 
rolled sheets of graphene which can be single or multi-walled. Nanotubes have potential 
applications in electronics, composite materials, the space elevator, and drug delivery.  
1994 - US science advisor, Dr. Jack Gibbons talks at the White House about nanotechnology 
and calls for increased . 
1997 - Zyvex, the first company to research nanotechnology, is founded.  
1999 - Consumer nanotech-based products start appearing on the global marketplace.  
2003 - Congress enacts the 21st Century Nanotechnology Research and Development Act.  
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2009 - The outlines a new research and regulatory strategy to better control the production 
and use of engineered nanomaterials. 
2010 - The House of Lords Science and Technology Committee, United Kingdom, warns its 
country's food industry against hiding its use of nanotechnology. 
Ideal properties of polymeric based Nanoparticles(Deepak Thassu.,et al., 2007) 
• Natural or synthetic polymer 
• Inexpensive 
• Nontoxic 
• Biodegradable 
• Nonthrombogenic 
• Nonimmunogenic 
 Nanoparticle recovery & drug incorporation efficiency 
(Leroueli Le Verger M., et al., 1998) 
Concentration of drug in Nanoparticles 
   Nanoparticles recovery %       =         X100  
Concentration of Nanoparticles recovered  
Drug incorporation efficiency has been expressed both as drug content (%w/w), also 
referred to as drug loading, & drug entrapment (%) represented by the following equation. 
Drug incorporation      Amount of drug entrapped in Nanoparticles 
efficiency in Nanoparticles  =   
             Total amount of drug added 
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1.2.1. Characterization of Nanoparticles. (Rakesh P. Patel.,et al., 2008) 
Table 1.1:Characterization of Nanoparticles 
Parameters Characterization methods 
Particle   size and  size 
distribution  
photon correlation spectroscopy, Scanning electron microscopy 
(SEM), Transmission electron microscopy (TEM), Atomic force 
microscopy (AFM), Mercury porositometry, Laser defractrometry 
Charge determination  Laser droplet anemometry, Zeta potentiometer  
Surface hydrophobicity  Water contact angle measurements, rose bangle (dye) binding, 
hydrophobic interaction chromatography, X-ray photoelectron 
spectroscopy  
Chemical analysis of 
surface  
Static secondary ion mass spectrometry, sorptometer 
Carrier drug interaction  Differential scanning calorimetry 
Nanoparticle dispersion 
stability  
Critical flocculation temperature(CFT)  
Release profile  In-vitro release characteristic under physiologic & sink condition  
Drug stability  Bioassay of drug extracted from nanoparticle, chemical analysis. 
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1.2.2. Classification of Nanoparticles.(Rakesh P. Patel., et al., 2008) 
1. In one dimensions (Thin surface coatings) 
One-dimensional systems, such as thin films or manufactured surfaces. 
2. In Two dimensions. 
a) Carbon Nanotubes 
Carbon nanotubes are a new form of carbon molecule. Wound in a hexagonal network 
of carbon atoms, these hollow cylinders can have diameters as small as 0.7 nm and reach 
several millimeters in length. Each end can be opened or closed by a fullerene half-molecule. 
These nanotubes can have a single layer (like a straw) or several layers (like a poster rolled in 
a tube) of coaxial cylinders of increasing diameters in a common axis. 
3. In three dimensions. 
a) Fullerenes (Carbon 60) 
Fullerenes are spherical cages containing from 28 to more than 100 carbon atoms 
displaying unique physical properties. They can be subjected to extreme pressures and regain 
their original shape when the pressure is released.  
b) Dendrimers 
Dendrimers represent a new class of controlled-structure polymers with nanometric 
dimensions. They are considered to be basic elements for large-scale synthesis of organic and 
inorganic nanostructures with dimensions of 1 to 100 nm, displaying unique properties. 
Compatible with organic structures such as DNA, they can also be fabricated to interact with 
metallic nanocrystals and nanotubes or to possess an encapsulation capacity 
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c) Quantum dots 
It represents a special form of spherical nanocrystals from 1 to 10 nm in diameter. 
They have been developed in the form of semiconductors, insulators, metals, magnetic 
materials or metallic oxides. 
 Types of Nanoparticles 
• Quantum Dots 
• Nanocrystalline silicon 
• Photonic 
• Liposome 
• Gliadin Nanoparticles 
• Polymeric Nanoparticles 
• Solid Lipid Quantum Nanoparticles 
• Others-Gold.Carbon, Silver.etc. 
1. Quantum dots 
A quantum dot is a semiconductor nanostructure that confines the motion of conduction 
band electrons, valence band holes, or excitons (pairs of conduction band electrons and 
valence band holes)in all three spatial directions. A quantum dothas a discrete quantized 
energy spectrum. A quantum dot4 contains a small integer number of the order of 1-100) of 
conduction band electrons, valence band holes, or excitons 
2. Nanocrystalline silicon. 
Nanocrystalline silicon is anallotropic form of silicon – is similar to amorphous silicon is 
sometimes also known as microcrystalline silicon. One of the most important advantages of 
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Nanocrystalline silicon, it has increasdstabilithovara  one of the reasons being because of its 
lower hydrogen concentration. 
3.Photonic crystals. 
Photonic crystals are periodic dielectric or metallo-dielectric (nano) structures that are 
designed to affect the propagation of electromagnetic waves (EM) in the same way as the 
periodic in a semiconductor crystal affects the electron motion by defining allowed and 
forbidden electronic energy bands. Photonic crystals are the attractive optical materials for 
controlling and manipulating the flow of light. They are of great interest for both fundamental 
& applied research, & are expected to find commercial applications soon. 
4.Liposomes. 
A Liposome is a spherical vesicle with a membrane composed of phospholipids bilayer 
used to deliver drugs or genetic material into a cell. Liposomes can be composed of naturally 
derived phospholipids wit mixed lipid chains(like egg, phosphatidylethanolamine), or of pure 
components . 
The use of liposomes for transformation or transfection of DNA into a host cell is known 
as lipofection . Liposomes can be created by sonicating phospholipids in water.  
5.Gliadin Nanoparticles. 
To improve bioavailability anti-H.pylori effects of antibiotics, 
mucoadhesivegliadin.Neutral amino acid can promote hydrogen bonding interaction with the 
mucosa whereas the lipophilic components can interact within biological tissue by 
hydrophilic interaction.  
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6.Polymeric Nanoparticles. 
Polymeric Nanoparticles have been invented by Speiser et al. They represent interesting 
alternative as drug delivery systems to liposomes. They usually exhibit a long shelf life & a 
good stability on storage. Nanoparticles can be prepared either from preformed polymers, 
such as polyesters (i.e.polylactic acid), or from a monometer during its polymerization, as in 
the case of alkylcyanoacrylates. 
 
                       Figure 1.5: Various Nanomedicine 
7.Solid lipid Nanoparticles. 
Solid Lipid Nanoparticles have been developed as alternative delivery system to 
conventional polymeric nanoparticles. SLNs are sub-micron colloidal carriers. 
Advantages. 
 Avoidance of coalescence leads to enhanced physical stability 
 Reduced mobility of incorporated drug molecules leads of drug leakage 
 Static interface solid/liquid facilitates surface modification. 
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8.Others 
Gold nanoparticles stabilized by thiol functionally are extraordinarily stable. A common 
synthesis involves the reduction of a gold salt in the presence of capping agent molecules 
such as thiols, citrates or phosphines. The synthesis of gold nanoparticles with a polymer-
thiol monolayer involves the mechanism of particle formation in the presence of bulky 
ligands. 
Gold nanoparticles are very good at scattering and absorbing light. It doesn’t stick as 
well to noncancerous cell. The results can be seen with a simple microscope. In the study, 
researchers found that the gold nanoparticles have 600 percent greater affinity 
 Advantages of Nanoparticles 
 Smaller dosage form (i.e., smaller tablet)  
 Decreased toxicity 
 Stable dosage forms of drugs which are either unstable or have unacceptable low 
bioavailability in non-nanoparticulate dosage forms.  
 Increased active agent surface area results in a faster dissolution of the active agent in 
an aqueous environment, such as the human body. Faster dissolution  generally 
equates with greater bioavailability, smaller drug doses, less toxicity.  
 Reduction in fed/fasted variability.  
 They are suitable for different routes of administration 
 Carrying capacity of nanoparticles is high 
 Shelf-stability of drug increases 
 Ability to sustain and control drug release patterns 
 Suitable for combination therapy where two or more drug can be co-deliverd 
 Both hydrophobic and hydrophilic drug can be incorporated 
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 System increases the bioavailability of drugs 
 Imaging studies can be done by utilizing them 
 It is used for targeted drug delivery of drugs 
 Development of new medicines  
 Toxicity and adverse drug interactions are reduced to a possible extent                                   
E.g. polymethacrylic nanoparticles for targeting anticancer drug of doxorubicin to reduce 
liver toxicity.Nanoparticles posses’ better stability as compared to leptosomes which make it 
more important for many modes of targeting. 
Nanoparticles formulated as amorphous offer solubility than standard crystalline 
formulations, thus improving the poor aqueous solubility of the drug and hence the 
bioavailability. 
 The methods of preparation are simple, easier and reproducible. 
 A high degree of patient compliance can be achieved. 
 Wide range of polymer can be used depends on the nature of the drug and usage i.e. 
biodegradable polymer for shorter periods, and non-biodegradable for longer periods. 
 It can easily pass through syringe needle and exhibit good rheological properties. 
Disadvantages of Nanoparticles.(Bshsagar., et al., 2010) 
 The manufacturing costs of nanoparticle are high which result in overall product cost 
 Solvents are toxic in nature which is used in the preparation process 
 Can start immune response and allergic reactions in body 
 Extensive use of poly (vinyl alcohol) as stabilizer may toxicity issues 
 According to a discovery, silver nanoparticles used in socks to fight foot odor if 
released in water can prove detrimental to the purity of water. 
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 Silver nanoparticles are bacteriostatic, by which we mean that they limit the growth of 
bacteria. This may result in the destruction of bacteria that help in breaking down the 
organic matter in water treatment plants. 
 The process of manufacturing nanomaterials results in the release of certain waste 
products. This waste can float in air or even penetrate animal and plant cells. 
 Nanoparticles have large surfaces. This makes them susceptible to get absorbed by 
macromolecules in an animal body. They can hinder biological processes, thus 
intervening the functioning of nature. 
 "Oral delivery via tablets or capsules is largely inefficient due to exposure of the 
pharmaceutical agent to the metabolic processes of the body. Therefore, a larger than 
necessary dose is often required and the maximum effectiveness of the drug is limited.  
 Traditional intravenous (IV) administration is much more problematic. Specificity for 
IV injectable drugs is often low, necessitating large amounts of a drug be injected into 
a patient, creating a high concentration of the drug in the blood stream that could 
potentially lead to toxic side effects". 
Limitations of Nanoparticle.(Randy P. Carney., et al., 2008) 
For example 
 Their small size and large surface area can lead to particles aggregation, making 
physical handling of nanoparticles difficult in liquid and drug formulations. 
 In addition, small particle size and large surface area readily result in limited drug in 
limited drug loading and burst release. These practical problems have to be overcome 
before nanoparticles can be used clinically or made commercially available. 
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Factors affecting the release of drugs from particulate carriers. 
(Soppimathk s., et al., 2001) 
Drug. 
 position of the particle  
 molecular weight 
 physicochemical properties 
 drug-carrier interaction 
 diffusion ; desorption from the surface Particles  
 type and amount of  matrix material 
 size and density of the particle 
 capsular(or) monolithic  
 extent and nature of any cross linking ; denaturation of polymerization ,presence of 
adjutants 
 surface erosion; particle diffusion and leaching 
 total disintegration of particles 
Environment. 
 hydrogen ion concentration 
 polarity 
 ionic strength 
 presence of enzymes 
 temperature. 
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Applications of Nanoparticles.(Rakesh P. Patel., et al., 2008) 
Table 1.2:Applications of Nanoparticles 
Nanomedicnes 
Nanodrugs, medical devices, tissue 
engineering, etc. 
 
Materials 
Nanoparticles, carbon nanotubes, biopolymers, 
paints, coating 
 
Chemicals and cosmetics 
Nanoscale chemicals and compounds, paints, 
coating, etc. 
 
Food science 
Processing, nutracetical food, nanocapsules 
 
Envirnoment and energy 
Water and air purification filters, fuel cells, 
photovoltics 
 
Military and security Sensers, wepons, sensory enhancement 
Electronics Semiconductor chips, memory storage, photonics, optoelectronics 
Scientific tools Atomic force, microscopes and scanning tunneling microscope 
Agriculture Pesticides, food production 
Therapeutic applications of Nanoparticles(Shoba Rani.,2008) 
 For intracellular targeting of anti-infective drugs to combat the ‘difficult to 
treat’ intracellular infections of the human body 
 For targeting of cytostatic drugs to reduce toxicity & increase therapeutic 
activity  
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 For specific targeting of anti-inflammatory drugs to areas of inflammation, by 
which the side effects of these  drugs can be minimized 
 For ocular delivery systems, to deliver pilocarpine and other miotic drugs 
 As carriers for radio nucleotides for diagnostic purpose in nuclear medicine 
 To improve the solubility and bioavailability of poorly soluble drugs 
 For skin and hair care in the form of solid lipid nanoparticles  wherein the 
oily core contains a wide variety of different cosmetic oils and lipophilic 
agents 
 To deliver drugs across the brain barrier (BBB) 
 To formulate sustained release preparations 
 For the controlled delivery of disinfectants or algaecides into large bodies of 
water such as insect pest feed on colloidal particles 
 For targeted delivery of proteins and peptides. 
1.2.3. Polymers employed for Nanoparticles .(Deepak Thassu .,et al., 2007) 
Synthetic polymers. 
 Polylactide co glycolic acid 
 Poly lactide 
 Polycaprolactone 
 Polymethyl methacrylate 
 Poly methyl methacrylate copolymer 
 Poly isobutylcyanoacrylate 
 Polyhexylcyanoacrylate 
 Ethyl cellulose 
 EudragitRL 
 EudragitRS 
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Natural polymers. 
 Gelatin 
 Lecithin 
 Albumin 
 Chitosan 
 Casein 
i. Natural biodegradable polymers used to prepare nanoparticles alginates 
Alginates are linear, unbranched polysaccharides composed of randomchains of 
Guluronic and mannuronic acids. In aqueous media, the sodium ions from salts of these 
anionic, heteropolymers exchange with divalent cations, such as calcium, to form water-
insoluble gels. Because of the favorable conditions during manufacture, alginates are 
ideal carriers for oligonucleotides, peptides, proteins, Water-soluble drugs or drugs that 
degrade in organic solvents. Alginates are non immunogenic and available in a wide 
range of molecular weights as characterized by their inherent viscosity. Alginate 
nanoparticles are prepared by extruding an aqueous sodium alginate solution through a 
narrow-bore needle into an aqueous solution of a cationic agent, such as calcium ions, 
chitosan, or poly-l-lysine. These cations cross-link the Guluronic and mannuronic acids to 
form an egg-box structure That forms the core of the gel matrix. In vivo, therapeutic 
agents are released whether matrix redissolves due to the reversible exchange of divalent 
cations with monovalentions, especially sodium present in physiological fluid.  
Chitosan 
Chitosan is a natural polymer obtained by deacetylation of chitin, a component of crab 
shells. It is a cationic polysaccharide composed of linear β (1, 4)-linked d-glucosamine.the 
various methods used to prepare chitosan-based nanoparticles and their applications has been 
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extensively reviewed. Chitosan can entrap drugs by numerous mechanisms including 
chemical cross-linking, ionic cross-linking, and Ionic complexation. 
Gelatin 
Gelatin is a natural, biodegradable protein obtained by acid- or base-catalyzed 
Hydrolysis of collagen. It is a heterogeneous mixture of single- or multi-stranded 
Polypeptides composed predominantly of glycine, proline, and hydroxyproline Residues and 
is degraded in vivo to amino acids. Gelatin nanoparticles are prepared by a two-step, de 
solvation process. The concentrated gelatin liquid particles are isolated and hardened by 
chemical cross-linking with glutaraldehyde. Alternately, these particles can be prepared using 
a simple o/w emulsion or w/o/w micro emulsion method. Gelatin nanoparticles have been 
used to deliver paclitaxel, methotrexate, doxorubicin, DNA, double-stranded 
oligonucleotides, and genes. Pegylation of the particles significantly enhances their 
circulation time in the blood stream and increases their uptake into cells by endocytosis. 
Antibody-modified gelatin nanoparticles have been used for targeted uptake by lymphocytes. 
Pullulan 
Similar to dextran and cellulose, the glucans in Pullulan are water-soluble, linear 
Polysaccharides that consist of three α-1, 4-linked glucose molecules polymerized By α-1,6 
linkages on the terminal glucose . Pullulan is a fermentation product of the yeast 
aureobasidiumpullulans. Pullulan nanoparticles have been prepared by Dialysis of an organic 
solution against water. In one method, a reverse micellar Solution of the anionic surfactant, 
aerosol, in n-hexane was prepared and an aqueous solution of the drug and Pullulan added. 
The nanoparticles are stabilized by cross-linking with glutaraldehyde. These delivery systems 
have been used in delivering cytotoxic drugs, genes, and as ph-sensitive delivery systems 
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Gliadin 
Gliadin is a glycoprotein that, as a component of gluten, is extracted from gluten rich 
food such as wheat flour. They are slightly hydrophobic and polar. Bioactive molecules of 
variable polarity can be encapsulated into gliadin nanoparticles. Gliadin nanoparticles can be 
prepared by a desolvation method that exploits the insolubility of this polymer in water. 
Briefly, gliadin nanoparticles are precipitated when an ethanolic solution of gliadin is poured 
into an aqueous solution. Gliadin nanoparticles have been used to deliver trans-retinoic acid, 
α-tocopherol, and vitamin e. Lectins have been conjugated to the surface of gliadin 
nanoparticles to target the colon and treat helicobacter pylori infections . 
ii. Synthetic biodegradable polymers used to prepare Nanoparticles 
Polylactide and polylactide-co-glycolide 
The hydrophobic PLA may be used alone or copolymerized with poly-glycolic acid to 
form a range of PLGA of widely varying polymeric ratios and hence physicochemical 
properties. These FDA-approved polymers have been widely used in drug delivery including 
nanoparticles. PLA and PLGA polymers degrade by random Bulk hydrolysis that is catalyzed 
in acidic media.  
Polyanhydrides 
Polyanhydrides are biodegradable polymers with a hydrophobic backbone and a 
hydrolytically labile anhydride linkage. They are synthesized by ring-opening Polymerization 
and degrade by surface hydrolysis. The application of Polyanhydrides has been limited to 
film and microsphere formulation for sustained release of a drug or protein at the site. 
Poly-є-caprolactones 
 Methods used to prepare nanoparticles using poly-ε-caprolactones have been previously 
reviewed and include emulsion polymerization, solvent displacement, Dialysis, and 
interfacial polymer deposition. These semi crystalline polymers are chemically stable, 
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possess a low glass transition temperature, and degrade slowly. Poly-ε-caprolactone 
Nanoparticles have been used as vehicles to deliver a wide range of drugs including 
tamoxifen, retinoic acid, and griseofulvin. 
Polyalkyl-cyanoacrylates 
Polyalkyl-cyanoacrylate nanoparticles are prepared by the conventional Emulsion-
evaporation technique. In addition to sustaining drug release, PACA Nanoparticles have the 
ability to overcome multidrug resistance at both the cellular and sub cellular levels. The 
potential for targeted delivery of PACA nanoparticles to cells has been demonstrated by 
conjugation of polysaccharides to the surface 
Non biodegradable polymers used to prepare Nanoparticles 
Polymethacrylate and Polymethyl methacrylate have been widely used in a variety of 
pharmaceutical and medical applications Incorporation of poly-acrylic acid into nanoparticles 
increased the transfection efficiency of DNA The side chain of PMMA can be modified to 
make these polymers possess ph-dependent solubility and has been used to prepare pH-
sensitive Nanoparticles to increase the oral bioavailability. 
1.2.4. Preparation techniques of Nanoparticles(Vyas S.P andKhar R.K., 2002) 
 The selection of the appropriate method for the preparation of nanoparticles depends on 
the physicochemical characteristics of the polymer and the drug to be loaded on the contrary; 
the preparation techniques largely determine the inner structure, in-vitro release profile and 
the biological fate of these polymeric delivery systems.  Two types of systems with different 
systems with different inner structures are apparently possible. 
 A matrix type of system consisting of an entanglement of oligomer or  polymer 
units(nanoparticles/nanospheres) 
 A reservoir type of system  comprised of an oily core surrounded by an embryonic 
polymeric shell(nanocapsules). 
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Structure of nanospheres and nanocapsules. 
  These methodologies are conveniently classified as follows. 
1. Amphiphillic macromolecule cross linking 
a. Heat cross linking 
b. Chemical cross linking 
Polymerization based methods 
a. Polymerization of monomers in situ 
b. Emulsion(micellar)polymerization 
c. Dispersion polymerization 
d. Interfacial condensation  polymerization 
e. Interfacial complexation. 
2. Polymer precipitation  methods 
a. Solvent extraction/evaporation 
b. Solvent displacement(nanoprecpitation) 
c. Salting out. 
 Several methods exist for the preparation of nanoparticles. When synthetic polymers are 
used, they are typically dissolved in a convenient solvent followed by precipitation in a liquid 
environment leading to nanoparticle formation. The drug intended to be encapsulated in the 
particles is usually incorporated in the process during the polymer solvation and precipitation. 
Emulsification/solvent diffusion, emulsification/solvent evaporation, nanoprecpitation and 
salting-out methods are widely applied techniques and they have been discussed in several 
reviews.  
Polymerization method (Mohanraj VJ and chen Y., 2006) 
 In this method, monomers are polymerized to form nanoparticles in an aqueous 
solution. Drug is incorporated either by being dissolved in the polymerization medium or by 
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adsorption onto the nanoparticles after polymerization completed.This technique has been 
reported for making polybutylcyanoacrylate or poly (alkylcyanoacrylate) nanoparticles 
Nanocapsules formation and their particle size depends on the concentration of the 
surfactants and    stabilizers used. 
Emulsion-solvent evaporation (Lamprecht Alf., 2009) 
Polymer and drug are dissolved in a suitable volatile solvent which is Immiscible with 
water. This solution is emulsified in an aqueous solution Containing stabilizer by 
conventional emulsification techniques. Droplet size can be further reduced by using a high-
energy source. Continuous emulsification under mixing prevents coalescence of organic 
droplets and allows the spontaneous evaporation of the solvent at room temperature and the 
formation of the colloidal particles. Following evaporation of organic phase under reduced 
pressure or vacuum produces a fine aqueous dispersion of nanoparticles. This technique was 
principally applied to the preparation of particles from water insoluble polymers. 
Solvent-displacement, -diffusion, or Nanoprecpitation(Beck-Broichsitter M., et al.,2010) 
A solution of polymer, drug and lipophilic stabilizer (surfactant) in a semi polar 
solvent miscible with water is injected into an aqueous solution (being a non-solvent or anti 
solvent for drug and polymer containing another stabilizer under moderate stirring. 
Nanoparticles are formed instantaneously by rapid solvent diffusion and the organic Solvent 
is removed under reduced pressure. The Velocity of solvent removal and thus nuclei 
formation is the key to obtain particles in the nanometer range instead of larger lumps or 
agglomerates. 
Salting-out  
Although a less common method of preparation, by adding a solution of polymer and 
drug in a water miscible solvent to an aqueous solution containing a salting -out agent and a 
stabilizer under stirring, small droplets can be obtained. Dilution of the resulting o/w 
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emulsion with water forces diffusion of organic solvent into the aqueous phase. The 
remaining polymer together with the drug produces particles in the nano-size range. The 
resulting dispersion often requires a purification step to remove the salting-out agent. 
In emulsification/solvent diffusion (Randy.et al.,2008) 
Nanoparticles are formed when the saturation limit of a partially water-miscible 
solvent ( Benzyl alcohol) is exceeded by addition of water. The phase separation is 
accompanied by vigorous stirring. The separated solvent is removed   by cross-flow filtration.  
Purification techniques of Nanoparticles.(Langmuir.,2010) 
Nanoparticles are intended to be used as pharmaceutical dosage forms in humans. 
Three important processes are performed. 
 Purification 
 Freeze-drying 
 Sterilization 
Purification of Nanoparticles. 
 In this method, various toxic impurities such as organic solvents, electrolytes, 
surfactants, stabilizers and large polymer aggregates can be found. Simple filtration will only 
remove polymer aggregates, while other impurities require sophisticated procedures. 
 Most common procedures. 
 Gel filtration. 
 Dialysis. 
 Ultracentrifugation. 
These methods are not satisfactory because they are restricted to the lab scale or incapable of 
eliminating molecules with high molecular weight. 
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Cross-flow filtration method. 
In this method, the nanoparticle suspension is filtered through membranes, with the 
direction of the fluid being tangential to the surface of the membranes.  
Freeze-drying of Nanoparicles. 
It is one of the method used to ensure the long-term conversation of polymeric 
nanoparticles 
Method. 
This technique involves the freezing of the suspension and the subsequent elimination 
of its water content by sublimation under reduced pressure. After complete desiccate, 
nanoparticles are obtained in the form of dry, free-flowing powder that is easy to handle and 
store. 
Sterilization of Nanoparticles 
Some of the well-established methods of sterilization such as filtration 0.22µm filters 
are not adequate for nanoparticle suspensions because microorganisms and nanoparticles are 
generally similar in size (0.3-1µm). Therefore, this method is best achieved by using aseptic 
techniques throughout their processing and preparation.  
Autoclaving (most heat sterilization) and Ỵ-irradiation are the techniques that can be applied 
for terminal sterilization. This technique may have impact on the physicochemical properties of 
the particles. 
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1.2.5.Main methods for the purification of Nanoparticles.(Mathlowitz Edith., 2009) 
Table 1.3:Main methods for the purification of nanoparticles on the laboratory scale 
Method Schematic Principle Drawback 
Gel filtration 
 
Removal of high molecular 
weight impurities difficult 
Dialysis 
 
Removal of high molecular 
weight 
Ultracentrifugation 
 
impurities difficult 
Various approaches to maintain the mechanism (Dong M. Shin., et al., 2007) 
Passive and active targeting. 
 Passive targeting approaches 
 Active targeting approaches. 
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Figure 1.6: various approaches to maintain the mechanism 
Passive targeting approaches. 
Takes advantage of natural anatomical structures or physiological processes, which 
direct carrier in vivo distribution. 
   Pathophysiological factors – Inflammation, Infection, EPR effect 
   Physicochemical factors     – Size, Molecular weight 
   Anatomical opportunities    – Catheterization, Direct injection 
   Chemical approaches          – Prodrugs, Chemical delivery systems. 
Active targeting approaches 
Carrier specificity can be enhanced, through surface functionalization with site-
directed ligands which bind or interact with specific tissues 
   Biochemical targets – Organs, Cellular, Organelles, Intracellular 
   Physical/External Stimuli     – Ultrasound, Magnetic field 
 Pretargeting/Sandwich targeting 
   Promoter/Transcriptional targeting. 
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Marketed products of novel formulations 
Table 1.4:Marketed products of novel formulations 
Company Trade name Composition Indication Administration 
Enzon Abelect Liposomal 
amphotericin B 
Fungal 
infection 
Intravenous 
Berna Biotech Epaxal Liposomal IRIV 
Vaccine 
Hepatitis A  Intramuscular 
Novavax Estrasorb Micellular 
estradiol 
Menopausal 
therapy  
Topical 
Nektar, 
Hoffmann- 
La Roche 
Pegasys PEG–a-
interferon 2a 
Hepatitis B,  
Hepatitis C  
Subcutaneous 
Genzyme Pegasys Poly(allylamine 
hydrochloride) 
End-stage 
renal disease  
Oral 
Health implications of Nanoparticles.(Rakesh P. Patel.,et al., 2008) 
Nanoparticles can enter the human body in several ways;  
(i)  The lungs where a rapid translocation through the blood stream to vital organs is possible, 
including crossing the BBB,  
(ii) The intestinal tract,  
(iii) The skin  
a) Skin 
Particles 500–1000 nm in size, theoretically beyond the realms of nanotechnology, 
can penetrate and reach the lower levels of human skin, 128 and smaller particles are 
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likely to move deeper into the skin  particles are often used in sunscreens to absorb UV 
light and therefore to protect skin against sunburn or genetic damage. It has been reported 
by Lademann et al in that micrometer-sized particles of  get through the human stratum 
corneum and even into some hair follicles – including their deeper parts. 
b) Intestinal tract 
The epithelium of the small and large intestines is in close contact with ingested 
material so that nutrients can be utilized. A mixture of disaccharides, peptides, fatty acids, 
and monoglycerides generated by digestion in small intestine are further transformed and 
taken in the villi.. Charged particles, such as carboxylated polystyrene nanoparticles or 
those composed of positively charged polymers exhibit poor oral bioavailability through 
electrostatic repulsion and mucus entrapment. The smaller the particle diameter the faster 
they could permutate the mucus to reach the colonic enterocytes; 14 nm diameter 
permeated within 2 min, 415 nm particles took 30 min, while 1000-nm particles were 
unable to translocate this barrier. 
c) Lung 
Based on three particle-types titanium dioxide , carbon black, and diesel particles, 
hazard studies in rats demonstrate that ultrafine or nanoparticles administered to the lung 
produce more potent adverse effects in the form of inflammation and subsequent tumors 
compared with larger sized particles of identical chemical composition at equivalent mass 
concentrations or intratracheally-instilled doses. Surface properties, such as surface 
chemistry and area, may play a significant role in nanoparticle particle toxicity. 
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1.3.Antilipedimicdrugs 
Lipids.(Anne Marie Helmenstine.,2005) 
The term 'lipid' was first used by the German biochemist Bloor in 1943 for a major 
class of tissue components and foodstuffs. 
A lipid is a fat-soluble molecule. To put it another way, lipids are insoluble in water 
but soluble in at least one organic solvent. The other major classes of organic compounds 
(nucleic acids, proteins, and carbohydrates) are much more soluble in water than in an 
organic solvent. Lipids do not share a common molecule structure.  
Lipids are biomolecules which are soluble in organic non-polar solvents. 
Consequently, fats and lipids are insoluble in water. Glycerides and waxes form a sub-group 
of compounds which have an ester as the major functional group and include.waxes, 
triglycerides, and phospholipids. Lipids without ester functional groups include.steroids, fatty 
acids, soaps, sphingolipids, and prostaglandins. 
 
 Figure 1.7: Life cycle of cholesterol 
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Definition of lipids(James Richard Fromm.,1977) 
A lipid is defined as a water-insoluble biomolecule which has a high solubility in 
nonpolar organic solvents such as chloroform. The simplest lipids are the fats, which are 
triesters made up of one glycerol and three fatty acids.  
The term fats is also used as a general synonym for lipids, so the more precise terms 
triacylglycerols or triglycerides are preferable for the simplest lipids. Triacylglycerols are 
used primarily for energy storage in animals. More complex lipids, the phospholipids, 
glycolipids, and cholesterol, are the major constituents of biological cell membranes. 
 
Figure 1.8: Types of lipids 
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Examples of common lipids(Charles E.Ophardt.,2003) 
Examples of common lipids include  
• Butter 
• vegetable oil 
• cholesterol and other steroids 
• waxes 
• phospholipids 
• Fat-soluble vitamins.  
Classification of lipids.(Charles E.Ophardt.,2003) 
Table 1.5:Classification of lipids 
 
Lipid Classification and Examples 
Fatty Acids Glycerides 
Saturated Fatty Acids Steroids 
Unsaturated Fatty Acids Lipoproteins 
Soap (salt of fatty acid) Triglycerides 
Prostaglandins Phosphoglycerides 
Non glyceride Lipids  
Waxes - 
Sphingolipids - 
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1.3.1. Lipid structure. 
Although there is no single common structure for lipids, the most commonly 
occurring class of lipids are triglycerides, which are fats and oils. Triglycerides have a 
glycerol backbone bonded to three fatty acids. If the three fatty acids are identical then the 
triglyceride is termed a simple triglyceride. Otherwise, the triglyceride is called a mixed 
triglyceride. 
The second most abundant class of lipids are the phospholipids, which are found in animal and 
plant cell membranes. Phospholipids also contain glycerol and fatty acids, plus the contain 
phosphoric acid and a low-molecular-weight alcohol. Common phospholipids include 
lecithinsand cephalins.  
The most important lipids present in blood plasma include fatty acids, triglycerides, 
cholesterol, phospholipids and steroid hormones. 
Triglycerides, cholesterol and phospholipids. 
Triglycerides are esters of fatty acids (e.g., stearic C-18 or palmitic C-16) and glycerols. Most 
of fatty acids are saturated, whereas nonsaturated fatty acids play an important role as 
prostaglandin precursors and in the process of cholesterol esterification.  
Cholesterol also is a cellular membrane element and precursor of steroid hormones 
and biliary acids. 
  Phospholipids are structurally similar to triglycerides, except that one minor acid is 
substituted by a phosphorous group and nitrogen base. 
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Functions of lipids(Charles E.Ophardt., 2003) 
 Fats and lipids are important because they serve as energy source, as well as storage 
for energy in the form of fat cells. 
 Lipids have a major cellular function as structural components in cell membranes. 
These membranes in association with carbohydrates and proteins regulate the flow of 
water, ions, and other molecules into and out of the cells. 
 Hormone steroids and prostaglandins are chemical messengers between body tissues. 
 Vitamins A, D, E, and K are lipid soluble and regulate critical biological processes. 
Other lipids add in vitamin absorption and transportation. 
 
Figure 1.9: Lipid function and metabolism 
Lipids act as a shock absorber to protect vital organs and insulate the body from temperature 
 Energy storage, mobilization, and utilization  
 Protection of organs  
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 Insulation  
 Storage of vitamins-ADEK  
 Hormone  production. 
Lipid metabolism impairments(Charles E.Ophardt., 2003) 
Assessment of lipid metabolism impairments is based on plasma concentrations of 
cholesterol and triglycerides, and on data obtained by lipoprotein electrophoresis. Therefore, 
a fasting period of 14-16 hours is required before blood sampling for analysis. Disorders due 
to lipid metabolism impairments are associated with a high risk of atherosclerosis 
 
Figure 1.10: Lipid metabolism impairments 
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Antilipidemicdrugs. (Tripathi K.D., 2004) 
Table 1.6:Antilipidemicdrugs 
1.4.HMG-CoA reductase inhibitors (Statins) 
 In 1980s, this type was the most efficacious and best tolerated hypolipidemic 
drugs. They competitively inhibit conversion of 3-Hydroxy-3-methyl glutaryl coenzyme A 
(HMG-CoA) to mevalonate (rate limiting step in CH synthesis) by the enzyme HMG-CoA 
reductase. Therapeutic doses reduce CH synthesis by 2-50%. This results in compensatory 
increase in LDL receptor expression on liver cells―›increased receptor mediated uptake and 
S.NO CLASSIFICATION NAME OF THE DRUGS 
1. HMG  - CoA reductase inhibitors (Statins). 
 Lovastatin 
 Simvastatin 
 Pravastatin 
 Atorvastatin 
 Rosuvastatin 
 Lovastatin 
2. Bile and sequestrants (Resins). 
 Cholestyramine 
 Colestipol 
3. 
 Active lipoprotein lipase (Fibric acid 
derivaties). 
 Clofibrate 
 Gemfibrozil 
 Bezafibrate 
 Fenofibrate 
4. 
Inhibit lipolysis and triglyceride synthesis 
 Nicotinic acid 
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catabolism of IDL and LDL. Over long term, feedback induction of HMG-CoA reductase 
tends to increase CH synthesis, but a steady-state is finally attained with a dose-dependent 
lowering of LDL-CH levels 
The daily dose for lowering LDL-CH by 30-35% is lovastatin 40mg, provastatin 40mg, 
simvastatin 20mg, atorvastatin 10mg, rosuvastatin 5mg. Moreover, maximum recommended 
doses simvastatin, atorvastatin and rosuvastatin can reduce LDL-CH by upto 45-55%, while 
the ceiling effect of lovastatin and pravastatin is 35-40% LDL-CH reduction. All statins 
produce peak V lowering after 1-2 weeks therapy. 
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Table 1.7: Mechanism of action and pattern of lipid lowering effect of important hypolipidaemic drug(Michael E. Maragoudakis., 1970)  
S.NO CLASSIFICATION NAME OF THE 
DRUGS 
DAILY 
DOSAGE 
MECHANISM OF ACTION EFFECT ON LIPIDS (%) 
 
 
1. 
 
 
HMG-
CoAreductaseinhibitors 
(Statins). 
Lovastatin (10-80mg)   
 
 LDL Decreased 20-55 
 HDL Increased 5-15 
 TG Decreased 10-35 
Simvastatin 
(5-40mg) 
 
Pravastatin   Decreased CH synthesis by inhibition of 
rate limiting HMG-CoA reductase 
Atorvastatin (10-80mg) 
Rosuvastatin (5-20mg) 
Lovastatin 
(10-80mg) 
 
2. 
 
Bile and 
sequestrants(Resins). 
 
Cholestyramine 
 
(4-16 mg)  Decreased bile acid absorption,  
 Increased hepatic conversion of CH to 
bile acids 
 Increased LDL receptors on hepatocytes 
 LDL Decreased 15-30 
 HDL Increased 3-5 
 TG not affected, may 
increased in some Colestipol (5-30 mg) 
 
3. 
 
Active lipoprotein lipase 
(Fibric acid derivatives). 
Clofibrate   
 Increased Activity of lipoprotein lipase 
 Decreased release of fatty acids from 
adipose tissue 
 
 LDL Decreased 5-20 
 HDL Increased 10-20 
 TG Increased 20-50 
Gemfibrozil (1200 mg) 
Bezafibrate 
(600 mg) 
Fenofibrate (200 mg) 
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HMG-CoA reductase pathway, which is blocked by statins via inhibiting the rate 
limiting enzyme HMG-CoA reductase. 
 
Figure 1.11:HMG-CoA reductase pathway, which is blocked by statins via inhibiting the rate 
limiting enzyme HMG-CoA reductase. 
The more effacious statins (simvastatin, atorvastatin, rosuvastatin) given at their highe doses 
effectively reduce (by 25% to 35%). Because HMG-CoA reductase activity is maximum at 
midnight, all statins are administered at bed time to obtain maximum effectiveness. But, this 
is not necessary for atorvastatin and rosuvastatin, which have long plasma t1/2 
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1.4.1.Other statins drugs. (Richard N. Fogoros, M.D.,2012) 
Lovastatin. 
 It is the first clinically used statin; is lipophilic and given orally in the precursor 
lactone form.  
 Lovastatin 40mg 
Systematic (IUPAC) name 
 1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-
1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate 
 Absorption – incomplete               
 Metabolism – bile   
 t1/2- short (1-4 hours) 
 Dose – 10 to 40 mg 
Simvastatin. 
It is a hypolipidemic drug used to control elevated cholesterol. Simvastatin is a 
member of the statin class of pharmaceuticals, is a synthetic derivate of a fermentation 
product of Aspergillusterreus. 
Systematic (IUPAC) name 
(1S,3R,7S,8S,8aR)-8-{2-[(2R, 4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl] ethyl}-
3, 7-dimethyl-1, 2,3, 7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate. 
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Absorption – incomplete               
Metabolism – bile  
t1/2- 2-3 hr 
Dose – 5 to 20 mg  
Pravastatin. 
Pravastatin (marketed as Pravachol or Selektine) is a member of the drug class of 
statins, used for lowering cholesterol and preventing cardiovascular disease. Initially known 
as CS-514, it was originally identified in a bacterium called Nocardiaautotrophica. It is also 
hydrophilic and given in the active form. 
Pravastatin 10 mg 
Systematic (IUPAC) name 
(3R, 5R)-3,5-dihydroxy-7-((1R,2S,6S,8R,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2 
methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)-heptanoic acid 
 Absorption – incomplete               
 CH lowering effect - less  
 t1/2- 1-3 hr 
 Dose – 40 to 80mg/day 
Atorvastatin. 
This newer statin is more potent and appears to have the highest LDL-CH lowering 
efficacy. All statins, including atorvastatin, prevent the production of cholesterol in the liver 
by blocking HMG-CoA reductase, an enzyme that makes cholesterol. 
Atorvastatin 40 mg 
t1/2 - 18 - 24 hr 
Dose – 10 to 40 mg 
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Rosuvastatin. 
This is the latest and the most potent statin (10 mg rosuvastatin ≈ 20 mg atorvastatin), 
crestor 10 mg 
t1/2 - 18 - 24 hr 
LDL-CH reduction – Greater 
TG levels – raised 
Dose – 5 mg 
Equivalentdosages of statin groups. 
Table 1.8:Equivalentdosages of statin groups 
% LDL 
Reduction 
(approx.) 
Atorvastatin Fluvastatin Lovastatin Pravastatin Rosuvastatin Simvastatin 
10-20% -- 20 mg 10 mg 10 mg -- 5 mg 
20-30% -- 40 mg 20 mg 20 mg -- 10 mg 
30-40% 10 mg 80 mg* 40 mg 40 mg 5 mg 20 mg 
40-45% 20 mg -- 80 mg* 80 mg* 5–10 mg 40 mg 
46-50% 40 mg -- -- -- 10–20 mg 80 mg* 
50-55% 80 mg -- -- -- 20 mg -- 
56-60% -- -- -- -- 40 mg -- 
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Adverse effects of statins.(Tripath K.D., 2006) 
 Headache 
 Nausea 
 Bowel upset 
 Sleep disturbances 
 Rise in serum transaminase, but liver damage is rare 
 Muscle tenderness 
 Myopathy 
Uses of statins.(Richard N. Fogoros., 2012) 
 Statins improve blood cholesterol levels primarily by inhibiting a liver enzyme called 
HMG Co-A reductase. 
 Reducing the size of plaques in the arteries.  
 Stabilizing plaques, so they are less likely to rupture (and therefore less likely to cause 
acute heart attacks).  
 Reducing inflammation (which is now thought to be an important component of 
plaque formation and rupture).  
 Reducing CRP levels 
 Decreasing blood clot formation (Blood clot formation at the site of plaque rupture is 
the cause of most heart attacks).  
 Improving overall vascular function. 
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2. NEED AND OBJECTIVES 
       Application of nanotechnology in drug delivery system has opened up new areas of research 
in controlled release of drugs. The nanoparticle represents promising drug delivery system of 
controlled and targeted drug release which shows and maintains the therapeutic concentration for 
long period of time. The reported bio- availability of  Rosuvastain is less. Hence the present 
study was undertaken to develop the bioavailability of the   drug. While forming the nanoparticle 
formulation it increased the absorption and bio- availability. The present work of nanoparticles 
are focused on Rosuvastatin loaded gelatin nanoparticle by two step desolvation method. Hence 
the novel  delivery system applied to antilipedimic drugs. Some biodegradable carriers degrade 
in the  body. This problem is overcome in this nanoparticles carriers. In long term therapy 
fluctuations in the plasma concentrations, with high concentration peaks are common for drugs 
with rapid absorption and elimination. Such characteristic makes Rosuvastatin is a suitable 
candidate for to prepare desired nanoparticulate drug delivery system. Rosuvastatin is the  widely 
used category of anti lipedimic drug in the treatment of high cholesterol condition.The aim of 
present work was to formulate  by using polymer like  gelatin A and Gelatin B  nanoparticles 
containing Rosuvastatin  in order to provide therapeutic effect.  
  2.1  Objectives   
•  Formulation of  gelatin loaded Rosuvastatin nanoparticles by two step desolvation 
method. 
• To characterize the nanoparticles for its physiochemical properties .  
•  To study the their in-vitro release profile and release kinetics. 
•  To perform Stability studies as per ICH guidelines. 
•  To Study the  zeta potenial 
  
Plan of work 
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• LITERATURE REVIEW 
• SELECTION OF DRUG, POLYMER  
• EXPERIMENTAL WORK 
a) PREFORMULATION STUDIES 
 Identification of drug 
 By FTIR spectroscopy 
 By melting point 
 Physicochemical parameters 
 Organoleptic properties 
 Solubility profile 
 Loss on drying 
 Analytical methods 
 Determination of λ max 
 Development of standard curve of Rosuvastatin  
 Determination of percentage purity of drug 
 Determination of compatibility  for drug with polymer 
 By DSC thermal analysis 
 Formulation of nanoparticles  
 By two step desolvation method 
 Determination of drug loading efficiency, drug loading capacity 
 Characterization of nanoparticles 
 By scanning electron microscopy 
 In-vitro dissolution studies 
 By dialysis bag method 
 Kinetics of drug release 
 Stability studies  
  Zeta potential 
3.PLAN OF  WORK 
  
Literature review 
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The   Literature  review  Indicating that   advancement in  nanoparticles drug delivery 
system is given below                                      
 Adlin jino nesalin J., et al., (2009) were developed and characterized nanoparticles 
containing  Flutamide .It is used in the treatment of prostate carcinoma having short  biological 
half life of 5-6 hrs. It is good candidate for the formulation of sustained release dosage form. coat 
ratio 1:4 gives better  sustained release for about 12 hrs as compared as other formulation. 
 Vandana singh A., et al., (2010) were developed and characterized  Rosiglitazone  
loaded gelatin nanoparticles by two step desolvation method. The sustained release of the drug 
could maintain the therapeutic concentration for long time. The encapsulation efficiency was 
found to be between in the range of 80-90%. The release profile was dependent on korsmeyer-
peppas equation. 
 Rahul Nair  K., et al., (2011) was formulated and evaluated on solid lipid nanoparticles 
of water soluble drug Isoniazed. The entrapment efficiency of drug in the SLN  has been 
improved. The SLNs were prepared  by ethanol injection method using tristearin and 
phospholipon 80 H using 32  factorial design. The different combination of tween 80 
concentrations and varied sonication time were used to prepare SLN. The prepared SLN were 
spherical in shape and process mean average size of 164.9 nm. It was for treatment of 
tuberculosis. 
 
4. LITERATURE REVIEW 
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Tamizharasi S., et al., (2009)  had prepared Lamivudine loaded polymethacrylic acid 
nanoparticles. They were  specially designed to release the drug in the vignity of  target tissue. It 
was prepared and evaluated polymethacrylic acid nanoparticles containing lamivudine in 
different drug and polymer ratio by nanoprecipitation method. The particle size was found to be 
121 to 403 nm. 
 Shanmughavel R., et al., (2010) In this study preparation and characterization of 
biopolymeric gelatin nanoparticles for encapsulating the antimicrobial drug Sulfadiazine and its 
vivo drug release  in phosphate buffer saline had been investicated. It was prepared by two step 
desolvation method. It had been proved to be effective treatment of meningococcal meningitis. 
The release was occurred upto 30% in a controlled manner. 
DongGon Kim., et al., (2006) had prepared the Retinol encapsulated chitosan 
nanoparticles, reconstitute in aqueous solution and application of cosmetic and pharmaceutical 
applications. These nanoparticles have a spherical shape and the obtained particle size is the 50 
to 200nm. Solubility of Retinol is able to increase by encapsulation into chitosan nanoparticles 
more than 1600-fold. X-ray diffractions patterns also showed that crystal peaks of retinol were 
disappeared by encapsulation into chitosan nanoparticles. 
  Joseph Nisha Mary S., et al., (2006) investigated a nanoparticles for the cancer 
treatment. Nanoparticles were prepared by the crosslinking method with different concentration 
of polymer, surfactant. So these nanoparticles showed a sustain release kinetics and good 
encapsulating properties. 
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   Kalaria  D., et al., (2008) were prepared Adoxorubicin loaded nanoparticles by emulsion 
method and stability studies was done in simulated fluids. The pharmacokinetic studies and 
toxicity studies were conducted in rats. So the nanoparticles showed good stability in simulated 
intestinal fluid and shows a sustain release, enhanced bioavailability and lower toxicity.  
  Kowsalya R., et al., (2005) was prepared and physicochemical evaluation of Cephalexin 
loaded polymethacrylic acid nanoparticles. The association of Cephalexin with nanoparticles was 
performed by emulsion polymerization in continuous aqueous phase. SEM indicated that 
Cephalexin nanoparticle have a discrete spherical structure without aggregation. The particle 
size, drug content and drug recovery of the nanoparticles was gradually increased with increase 
in the proportion of polymethacrylic acid polymer. The in-vitro release studies indicated that 
Cephalexin nanoparticles provide sustained release over a period of 21hours and follow zero 
order kinetics. 
 Lieven Baert., et al., (2009) developed a long acting formulation containing Rilivirine 
nanoparticles for HIV treatment. The Nanosuspensions were prepared by wet milling in aqueous 
carrier. The obtained particle size is 200-800nm and stable for six months, stability up to six 
months. Following single dose administration 3 months in dogs and 3 weeks in mice shows the 
sustain release 
  Muhammad Rafeeq P., et al., (2010)   the objective of our study is to load first line anti 
tubercular drug, Isoniazid in chitosan nanoparticles in order to enhance bioavailability and to 
reduce dose frequency. Chitosan was dissolved in acetic acid aqueous solution at various 
concentrations, drug was dispersed in above chitosan solution kept over magnetic stirrer at room 
temperature for a period of 30 minute. The tripolyphosphate aqueous solution with various 
concentrations added drop wise to the above sonication and centrifugation with ultracentrifuge. 
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After freeze drying the nanoparticles were collected. SEM studies show that formulation no 2 
having optimum nanosized particles. Zeta potential shows good positive potentials. It shows 
good encapsulation efficiency. And good release profile follows first order release kinetics 
 Qiang zhang., et al., (1999) stearic acid nanoparticles were prepared in this study by 
melt-homogenization to investigate the possibility of them as a new kind of drug carrier system.  
Cyclosporine a as a model drug was then encapsulated into stearic acid nanoparticles. Following 
the establishment of  assay for cyclosporine a analysis in stearic acid nanoparticles or blood 
samples, the encapsulation ratio of cyclosporine a to stearic acid nanoparticles was estimated and 
pharmacokinetics as well as bioavailability of cyclosporine a stearic acid nanoparticles after oral 
administration to wistar rats were studied. The mean diameter of cyclosporine a stearic acid 
nanoparticles was 316.1 nm, while the encapsulation ratio of cyclosporine a to stearic acid 
nanoparticles reached to 88.36%. The relative bioavailability of cyclosporine a stearic acid 
nanoparticle over reference was nearly 80%, and the time to reach maximum concentration of 
Cyclosporine. 
YoungWook., et al., (2008) was developed the natural gelatin based nanoparticles by 
method of modified desolvation by natural cross linker for protein drug delivery. The obtained 
recombinant human gelatin nanoparticles deliver a modified protein in sustained release manner 
without initial burst.  
Yungchih kuo., et al., (2005) was performing the loading efficiency of Rosuvastatin, a 
human immunodeficiency antiretroviral agent, on the external surfaces of 
polybutylcyanoacrylate and methylmethacrylatesulphopropylmethacrylate, were prepared. The 
experimental results indicate that the larger the polymeric nanoparticles, the smaller loading 
efficiency of Rosuvastatin on the two kinds of biomaterials. Freeze-drying of the two 
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nanoparticles, however, yields an increase in particle size and an increase in loading efficiency of 
Rosuvastatin, in general. Stability studies at 4◦C over 6 weeks leads to an increase in particle size 
and a decrease in loading efficiency of Rosuvastatin.  Loading efficiency of Rosuvastatin on both 
of the two nanoparticles decreases with a variation in pH value. 
Yvette Konan N., et al., (2002) had studied on preparation and characterization of sterile 
and freeze dried nanoparticles. By using salting out procedure to produced the sub-200nm 
nanoparticles. After freeze drying complete dispersion of all the types of polyester nanoparticles 
in presence of lyoprotectants such as saccharides and the sterility testing showed that no 
microbial contamination. 
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5. DRUG AND POLYMER PROFILE 
 
5.1: Drug profile (McTaggart F., et al., 2001) 
CRESTOR (Rosuvastatin calcium) is a synthetic lipid lowering agent for oral administration. 
Rosuvastatin is an antilipidemic agent that competitively inhibits hydroxymethylglutaryl-
coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-
CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to 
a class of medications called statins and is used to reduce plasma cholesterol levels and prevent 
cardiovascular disease. 
Brand name 
 Astende (Lazar (Argentina))  
 Cirantan (AstraZeneca (Netherlands))  
 Cresadex (Drugtech (Chile))  
 Crestor (AstraZeneca)  
 Provisacor (AstraZeneca (Italy, Netherlands) )  
 Razel (Glenmark (India))  
 Rosedex (Roux-Ocefa (Argentina))  
 Rosimol (Sandoz (Argentina))  
 Rosumed (Labomed (Chile))  
 Rosustatin (Montpellier (Argentina))  
 Rosuvas (Ranbaxy (India))  
 Rosuvast (Bago (Argentina))  
 Rosvel (Laboratorios Chile (Chile))  
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Chemical data 
 Molecular formula     : (C22H27FN3O6S)2Ca 
 Molecular  weight        : 1001.1 g/mol 
 Solubility   :sparingly soluble in water and methanol and slightly soluble in  
ethanol.  
 Melting point                : 155.4°C  to 155°C 
 Colour                   : Off-white to creamish white crystalline powder. 
 Plasma concentration : reached in 3–5 hour 
Molecular structure: 
 
 
Category:(McTaggart F., et al., 2001) 
 Anticholesteremic Agents  
 HMG-CoA Reductase Inhibitors 
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Pharmacokinetics  data 
Bioavailability- 20% 
Metabolism- Liver 
Half-life- 19 h 
Excretion- Urine / Faeces 
Volume  - 134L 
Protein binding- 90% 
a) Absorption: 
 Bioavailability is approximately 20% 
b) Distribution:  
Rosuvastatin is 88% bound to plasma proteins, mostly albumin. This binding is reversible 
and independent of plasma concentrations.    
c)Volume of distribution: 
 134 L/kg 
 
d) Metabolism: 
Rosuvastatin is not extensively metabolized; approximately 10% of a radio labeled dose is 
recovered as metabolite. The metabolite is N- desmethylRosuvastatin, which is formed 
principally by cytochrome P450 2C9, and in vitro studies have demonstrated that N- 
desmethylRosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase 
inhibitory activity of the parent compound. Overall, greater than 90% of active plasma HMG-
CoA reductase inhibitory activity is accounted for by the parent compound.   
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e) Excretion:  
Following oral administration, Rosuvastatin and its metabolites are primarily excreted in the 
feces (90%). After an intravenous dose, approximately 28% of total body clearance was via the 
renal route, and 72% by the hepatic route. 
5.1.1:Mechanism of action(Tripathy K.D., 2008) 
Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-
limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a 
precursor of cholesterol. First, it increases the number of hepatic LDL receptors on the cell 
surface to enhance uptake and catabolism of LDL. Second, Rosuvastatin inhibits hepatic 
synthesis of VLDL, which reduces the total number of VLDL and LDL particles. 
Rosuvastatin pathway 
Rosuvastatin inhibits cholesterol synthesis via the mevalonate pathway by inhibiting 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase is the 
enzyme responsible for the conversion of HMG-CoA to mevalonic acid, the rate-limiting step of 
cholesterol synthesis by this pathway. The active form of statins bears a chemical resemblance to 
the reduced HMG-CoA reaction intermediate that is formed during catalysis. Unlike Lovastatin 
and simvastatin, which undergo in vivo hydrolysis to their active form Rosuvastatin is 
synthetically produced in active form. Cholesterol biosynthesis accounts for approximately 80% 
of cholesterol in the body; thus, inhibiting this process can significantly lower cholesterol levels. 
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Figure 5.1: Rosuvastatin pathway 
5.1.2: Adverse effects 
Drug interactions    (Kristi Monson., et al.,2011) 
 Cyclosporine 
 Gemfibrozil 
 Lopinavir/Ritonavir 
 Coumarin Anticoagulants 
 Niacin 
 Fenofibrate 
Contraindications  
 Hypersensitivity reactions including rash, pruritus, urticaria and angioedema 
 Active liver disease 
 Elevations of hepatic transaminase levels 
 Pregnant women 
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Dosage forms 
 5 mg: Yellow, round, biconvex, coated tablets.  
 10 mg: Pink, round, biconvex, coated tablets.   
 20 mg: Pink, round, biconvex, coated tablets.  
 40 mg: Pink, oval, biconvex, coated tablets.  
5.2Polymer profile(Wayne Goates Kansas., et al., 2003) 
 Gelatin is a natural, biodegradable protein obtained by acid- or base-catalyzed Hydrolysis 
of collagen. It is a heterogeneous mixture of single- or multi-stranded Polypeptides composed 
predominantly of glycine, proline, and hydroxyproline Residues and is degraded in vivo to 
amino acids. Gelatin nanoparticles are prepared by a two-step, de solvation process. The 
concentrated gelatin liquid particles are isolated and hardened by chemical cross-linking with 
glutaraldehyde. Alternately, these particles can be prepared using a simple o/w emulsion or 
w/o/w micro emulsion method. Gelatin nanoparticles have been used to deliver paclitaxel, 
methotrexate, doxorubicin, DNA, double-stranded oligonucleotides, and genes. Pegylation of the 
particles significantly enhances their circulation time in the blood stream and increases their 
uptake into cells by endocytosis. Antibody-modified gelatin nanoparticles have been used for 
targeted uptake by lymphocytes. 
Description: 
Gelatin occurs as a light-amber to faintly yellow-colored, vitreous, brittle solid. It is 
practically odorless and tasteless and is available as translucent sheets add granules. 
Gelatin contasins: 
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• 84-90% protein  
• 1-2% mineral salts  
• 8-15% water  
• It is free from additives and preservatives  
Types of gelatin:(GMAP Publishers, 2005) 
Two main types of gelatin. 
Type A, is derived from collagen with exclusively acid pretreatment.  
Type B, is the result of an alkaline pretreatment of the collagen. 
Typical specifications for Type Aand Type B are:  
Table 5.1: Typical specifications for Type Aand Type B 
Parameter Type A Type B 
pH 3.8 - 5.5 5.0 - 7.5 
Isoelectric Point 7.0 - 9.0 4.7 - 6.0 
Gel strength (bloom 50 – 300 50 - 300 
Viscosity (mps) 15 – 75 20 - 75 
 
Chemical formula :C102H151039N31 
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5.2.1:Bio physicochemical properties of gelatin 
 Color: color varying from a very pale yellow to dark amber 
 Physical appearance:  Occurs as flakes. 
 Viscosity: 
 4.3-4.7 mPa s (4.3-4.7 cP) for a 6.67% w/v aqueous solution at 60.c 
 18.5-20.5 mPa s (18.5-20.5 cP) for a 12.5% w/v aqueous solution at 60.c 
 Molecular weight: 15000 – 250 000 
5.2.2:The most favorable operating conditions for the extraction of gelatin are: - 
Table  5.2:  The extraction of gelatin 
STAGES TEMPERATURE TIME PH 
First stage 64 oC 5 hr 7 
Second stage 74 oC 3.72 hr 7 
Third stage 84 oC 3.69 hr 7 
Fourth stage 98 oC , 3.83 hr 7 
 
5.2.3: Chemical properties of gelatin: 
 Together with water, it forms a semi-solid colloidgel.  
 Gelatin forms a solution of high viscosity in water,  
 Gelatin solutions show viscoelastic flow and streaming birefringence.  
 Gelatin is put into contact with cold water, some of the material dissolves.  
 solubility of the gelatin is determined by the method of manufacture. 
 Gelatin is also soluble in most polar solvents.  
 Gelatins are very sensitive to temperature variations. 
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 The viscosity of the gelatin/water mixture increases with concentration and when kept 
cool (≈ 4 °C).  
 There are also vegetable gelatins such as agar. 
Safety: 
In general, when used in oral formulations gelatin may be regarded as a nontoxic & 
nonirritant material. Gelatin capsules adhering to the esophageal lining which may cause local 
irritation. 
Handling precautions: 
Eye protection and gloves are recommended. Gelatin should be handled in a well-
ventilated environment 
Uses of gelatin:(Wayne GoatesKansas., et al., 2003) 
 binders for paper money 
 cosmetics 
 bonding for the tip of matches 
 bakery products 
 photographic film 
 whipping agent in dairy products 
 medicine emulsions 
 hardening of jams and jellies 
 treatment of wounds as a sponge 
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5.2.4:Pharmaceuticalaspects of gelatin: (GMAP Publishers, 2005) 
P   Gelatin is the most pure and perfect protein  
       available 
H    It is absolutely harmless and controlled by high quality standards for such    
       applications 
A    Active and readily and rapidly accepted by the  
       body 
R    Reliable and safe ingredient in sensitive products 
M    Significant in medicinal and medical applications 
A    Contains practically all essential amino acids  
       required for body cells and tissue nourishment 
C    Sourced from natural collagens 
E    Essential to all humans 
U    A unique and useful product used through the  
       centuries 
T    Significant in thermoreversible and tabletting applications 
I      Truly an international product 
C    A clear and clean product 
A    Easily available from several producers who are  
       members of gmap 
L    Used in several life supporting applications, such as  
       plasma extenders. 
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Pharmaceutical applications: (Sylvie Audoly., et al., 2006) 
Hard capsules 
 Hard capsules are composed mainly of gelatin, and eventually of an opacifier and 
coloring agents. They are obtained by dipping metallic formers called pins, into the gelatin 
solution, removing and allowing the solution to gel in the air and dry. Pharmaceutical customer 
will fill the hard capsules mainlywith powders or solid forms (tablets, …), but with the 
improvement of the technology including the sealing of the capsules to avoid leakage, hard 
capsules can also be filled with liquids or pastes when it was dedicated to soft capsules few 
years ago. The resistance, the elasticity and the solubility of the shell will depend on physical 
characteristics of the gelatin.  
Soft capsules 
Softgels are a one-piece, hermetically sealed capsule with an outer shell made of    
gelatin, water, plasticizers (glycerol, sorbitol,…) which gives elasticity and softness to the walls 
and sometimes coloring  agents plus opacifier. Medium Bloom are preferred for elasticity and 
easiness to work on the machine. In this technology, the encapsulation of the drugs (oily 
products, non aqueous liquids, suspension and  astes…) is made simultaneously with the 
formation of the walls. The main process used is the rotary die process. 
Tablets 
 Gelatin is used for its binding properties. Used in direct compression or after granulation 
of the powder to be used in compression, gelatin or hydrolyzed collagen allow to give 
cohesiveness,resistance, hardness to the tablet. 
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Bloodplasma 
  Blood plasma substitute replaces blood when large volumes are lost during anaccident for 
example and without knowing the blood grouping. Most of the time in Europe, blood plasma 
substitute consists of pyrogene free water, gelatin and salts (chlorides), while in the USA starch 
preparation are mainly used.Blood plasma substitute reestablishes the blood pressure with the 
presence of relatively low molecular weight molecules. One of the advantages of plasma 
substitute based on gelatin is the absence of  accumulation effect into the body (as it could 
happen with starch) due to a reasonably rapid elimination by the metabolism or excretion. 
Cholostomy bags 
 Gelatin is used in association with other polymers as CMCor pectines and anadhesive to 
obtain a sticking ring allowingto fix cholostomy bags and to absorb themoisture ofthe skin. 
Sticking, coating and water binding properties ofgelatin are especially interesting in that case. 
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6. MATERIALS AND EQUIPMENTS 
6.1: Raw materials 
Table 6.1: Raw materials with name of the supplier 
S.No Name of raw material Name of the supplier 
1 Rosuvastatin 
Torrent pharmaceuticals 
Ltd, Ahmedabad 
2 Gelatin – A S.D fine-chem limited, Mumbai. 
3 Gelatin – B S.D fine-chem limited, Mumbai. 
4 Glutaraldehyde 25% S.D fine-chem limited, Mumbai. 
5 Distilled water Apex, Chennai. 
6 Acetone Apex, Chennai. 
7 Sodium sulfate S.D fine-chem limited, Mumbai. 
8 Sodium metabisulfite S.D fine-chem limited, Mumbai. 
9 Chloroform S d fine-chem limited, Mumbai. 
10 Methanol Qualigens fine chemicals, Mumbai. 
11 Ethanol (95%) S d fine-chem limited, Mumbai. 
12 Propylene glycol NR chemicals, Mumbai. 
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6.2: Equipments 
Table 6.2:  Equipments with company name 
S.No Name of the Equipments Company 
1 Electronic balance Shimadzu BL-220H 
2 Sonicator  
2200MH, Soltech srl,  Soluzioni 
Tecnologirhe, Milano, italy 
3 Magnetic stirrer 
1-MLH, remi equipments limited, 
vasai 
4 Freeze drying apparatus Lyostar, S.P biotech limited. 
5 Scanning electron microscope Model-s-3400N, SEM HITACHI 
6 Zeta potential Zetasizer, Malvern, UK 
7 Photon correlation spectroscopy Malvern instruments, Germany  
8 pHmeter  LI120 pHmeter, ELICO LTD  
9 Humidity chamber Labtech 
10 Rotary shaker 
RS-12R, remi equipments limited, 
vasai 
11 UV spectrophotometer 
Shimadzu-1700 Pharmaspec UV 
VISIBLE spectrophotometer 
12 FTIR spectrophotometer Shimadzu S4008 
13 Differential scanning calorimeter Shimadzu  DSC 60, Japan 
14 Micro ultra centrifuge Remi equipments limited, vasai 
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7.1. Preformulation studies 
Preformulation testing was an investigation of physical and chemical properties of a drug 
substance alone. It was the first step in rational development of dosage form. 
7.1.1. Identification of drug  
7.1.1.1. Identification by FTIR spectroscopy(SkoogD.A.,et al.,1996;IP, 2007) 
Rosuvastatin discs were prepared by pressing the Rosuvastatin with potassium bromide 
and the spectra between 4000-1 to 500-1 cm was obtained under the operational conditions. The 
absorption maximums in spectrum obtained with the substance being examined correspond in 
position and relative intensity to those in the reference spectrum  in Table 8.1 and Figure 8.1 
7.1.1.2. Identification by melting point (IP, 2007) 
Melting point of the drug was determined by capillary tube method. 
7.1.2. Physicochemical parameters 
7.1.2.1. Organoleptic properties(Lachman L., et al., 1991; Bankar G.S. and Rhodes C.T., 1996) 
 The color, odor and taste of the drug were recorded using descriptive terminology. 
7.1.2.2. Solubility study (Merck Index, IP, 2007) 
It is important to know about solubility characteristic of a drug in aqueous system, since 
they must possess some limited aqueous solubility to elicit a therapeutic response. The solubility 
of drug was recorded by using various descriptive terminology specified in Indian 
pharmacopoeia, 2007.The solubility study was shown in Table 8.2. 
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7.1.2.3. Loss on drying(IP, 2007) 
Loss on drying is the loss of weight expressed as percentage w/w resulting from water and 
volatile matter of any kind that can be driven off under specified condition. The accurately 
weighed 1gm of sample was transferred instoppered-glass shallow weighing bottle and 
accurately weighed the bottle. The bottle was transferred in oven and substance was dried at 
105°C for 3 hours. The bottle was removed from oven and reweighed; loss on drying was 
calculated by following equation,.It was shown in Table 8.3 
𝐋𝐋𝐋𝐋𝐋𝐋 =  𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈 − 𝐅𝐅𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈
𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈
× 𝟏𝟏𝟏𝟏𝟏𝟏 
7.1.3. Analytical methods 
7.1.3.1. Determination of λ max (Alka Gupta., et al., 2005) 
The absorption maximum of the standard solution was scanned between 200-400 nm regions on 
UV-VISIBLE spectrophotometer. The absorption maximum obtained with the substance being 
examined corresponds in position and relative intensity to those in the reference spectrum  
Development of standard curve of Rosuvastatin in methanol: (Alka Gupta., et al., 2005) 
25 mg of Rosuvastatin Calcium was weighed accurately and transferred into 50 ml 
volumetric flask and dissolved in Methanol, after dissolution the volume was made up to the 
mark with Methanol (500µg/ ml). Further dilution was made by    pipetting 1 ml of mother liquor 
into 50 ml s to acquire 10 µg/ ml solution  made up with methanol. The absorbance 
measurements of these solutions were carried out against methanol as blank at 244 nm. A 
calibration curve of Rosuvastatin was plotted. 
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Preparation of methanol solution(IP, 2007) 
Methanol was prepared according to I.P. 2007.  
Preparation of stock solution of Rosuvastatin in methanol: 
Accurately weighed 100 mg of Rosuvastatin was dissolved in little quantity of 100ml of 
methanol and 1ml of solution was taken & make up to 10ml (100µg/ml) volume was the same to 
prepared standard solution having concentration of 100 µg/ ml.  
Procedure: 
From the stock solution, aliquots of 1, 2, 3, 4, 5,6 and 7 ml were transferred to 10 ml 
volumetric flasks and final volume was made to 100ml with methanol. Absorbance values of 
these solutions were measured against blank (methanol) at 244 nm using uv-visible 
spectrophotometer 
Development of standard curve of Rosuvastatin in 6.8 phosphate buffer:(IP, 2007) 
Preparation of 6.8 phosphate buffer: 
 Place the 50 ml of 0.2M potassium dihydrogen phosphate in a 200 ml of volumetric 
flask.And add specified volume of 0.2 M sodium hydroxide then add water to volume to 
required. 
Preparation of 0.2 M sodium hydroxide: 
 Dissolve the sodium hydroxide in water to produce 40 to 60 %w/v solution and allow to 
stand and finally add 8 gm of sodium hydroxide  in 1000 ml. 
Preparation of  0.2 M potassium dihydrogen phosphate: 
 Dissolve the 27.218 gm of potassium dihydrogen phosphate in water to dilute with water 
1000ml. 
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Preparation of stock solution of Rosuvastatin in 6.8 phosphate buffer: 
Accurately weighed 100 mg of Rosuvastatin was dissolved in little quantity of 100ml of 
6.8 phosphate buffer and 1ml of solution was taken & make up to 10ml (100µg/ml) volume was 
the same to prepared standard solution having concentration of 100 µg/ ml.  
Procedure: 
From the stock solution, aliquots of 1, 2, 3, 4, 5,6 and 7 ml were transferred to 10 ml 
volumetric flasks and final volume was made to 100ml with methanol. Absorbance values of 
these solutions were measured against blank (6.8 phosphate buffer) at 240 nm using uv-visible 
spectrophotometer 
Determination of percentage purity of drug (Dhirendra K., et al., 2010; IP, 2007) 
Standard solution Preparation: 
Standard solution of Rosuvastatin calcium was prepared by dissolving 10mg of 
Rosuvastatin calcium in 100ml of methanol. To obtained the concentration 100µg/ml. Further 
diluted 5-50ml by same solvent to obtained a solution containing 10µg/ml. 
Sample solution preparation: 
Pure raw materials of Rosuvastatin calcium were weighed and powdered. Amount of 
powdered equivalent to 20 mg taken into a 200ml volumetric flask, 140 ml methanol added to 
dissolve the drug, cooled the flask up to the room temperature and methanol was added to make 
up the volume up to the mark,Centrifuged at 4000 rpm for 10mins, further diluted 5ml to 50ml 
with same solvent to obtain a solution containing 10 μg/ml. Same procedure was used for two 
other market samples of Rosuvastatin calcium. 
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Determination of drug-polymer compatibility (Patil.,et al., 2009) 
The proper design and formulation of a dosage form requires consideration of the 
physical, chemical and biological characteristics of all drug substances and excipients to be used 
in the fabricating the product. Each polymer used in the formulations was blended with the drug 
levels that are realistic with respect to the final dosage form.  
 
Figure 7.1:Compatibility studies 
Fourier transforms infra-red (FTIR) spectroscopy   (Patil S.V., et al., 2009; IP, 2007) 
FTIR study was carried out to check compatibility of drug with polymers. Infrared 
spectrum of Rosuvastatin was determined on Fourier transform Infrared Spectrophotometer 
using KBr dispersion method. The base line correction was done using dried potassium bromide. 
Then the spectrum of dried mixture of drug and potassium bromide was run followed by drug 
with various polymers by using FTIR spectrophotometer. The absorption maximums in spectrum 
obtained with the substance being examined correspond in position and relative intensity to those 
in the reference spectrum . 
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Differential scanning calorimetry (DSC) (Patil S.V., et al., 2009;Aulton  M. E., 2002) 
Any possible drug polymer interaction can be studied by thermal analysis. The DSC 
study was performed on pure drug, drug+ Gelatin. The study was carried out using a DSC. The 2 
mg of sample were heated in a hermetically sealed aluminum pans in the temperature range of 
25-300ºc at heating rate of 10ºc /min under nitrogen flow of 30ml/min 
7.2:Preparation of Nanoparticles(Ze Lu et al.,2004) 
The nanoparticles were prepared by in-situnanoemulsion polymer Two step desolvation method, 
by using a different drug and polymer ratios. The formulations were designated as F-1, F-2, F-3, 
F-4, F-5, F-6, F-7 and F-8respectively.  
Table7.1: The compositions of formulations 
S.NO Formulations 
Ingredients 
(gm) 
Gelatin A ratio Gelatin B ratio 
F1 
(1:1) 
F2 
(1:2) 
F3 
(1:3) 
F4 
(1:4) 
F5 
(1:1) 
F6 
(1:2) 
F7 
(1:3) 
F8 
(1:4) 
Rosuvastatin 1 1 1 1 1 1 1 1 
Gelatin A 1 2 3 4 - - - - 
Gelatin B - - - - 1 2 3 4 
Sodium sulphate 
(20%) ml 
2 2 2 2 2 2 2 2 
Sodium 
megabisulphate 
(12%) ml 
5 5 5 5 5 5 5 5 
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Two step desolvationmethod:(Ze Lu et al.,2004) 
Gelatin (200 mg) was dissolved in 10 ml of water containing of 2% Tween 20. The 
solution was heated at 40°C with constant stirring at 300 rpm. To this solution, 2 ml of a 20% 
aqueous solution of sodium sulfate was added slowly, followed by 1  of isopropanolcontaining2 
mg of Rosuvastatin. A remaining of sodium sulfate solution (5.5–6 ml) was added  
untilthesolution turned turbid, (which indicated the formation of gelatin aggregates.) 
Approximately 1 ml of distilled water was then added until the solution turned clear. An aqueous 
solution of glutaraldehyde[25%, (0.4 ml)] was added to cross-link with the gelatin. Sodium 
metabisulfitesolution [12%, (5 ml)] was addedafter  5 minutes  to stop the cross-linking process. 
After 1 hour, the crude product was purified on a Sephadex G-50 column. The nanoparticle 
containing fraction was lyophilized in a freeze drier over a 48 hour period. 
7.3. Characterization of Nanoparticles 
7.3.1. Characterization of Rosuvastatinloaded gelatin Nanoparticles  
Encapsulation efficiency(vandanasingh ., et al., 2010) 
The determination of drug entrapment, the amount of drug present in the clear 
supernatant after centrifugation was determined(w) by spectrophotometry at 240 nm. A standard 
calibration curve of drug was plotted. The amount of drug in the supernatant was then subtracted 
from the total amount of drug added during the preparation (W). Effectively (W-w) will give the 
amount of drug entrapped in the pellet.  
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            Amount of drug bound by total amount of   nanoparticles 
Drug encapsulation efficiency =         x100     
                                                                 Amount of drug taken.       
 
Particle size distribution (MaincentPandKimy., 1997)   
Every sample was diluted with phosphate buffered saline pH 6.8.The surface charge (Zeta 
potential) was determined by measuring the electrophoretic mobility of nanoparticles using a 
Malvern zeta sizer. Samples were prepared by dilution with phosphate buffer saline pH 6.8. The 
zeta potential value was calculated by the software using Smoluchowski’sequation.It was shown 
in Figure 8.15 
Scanning electron microscopy (SEM) 
The surface morphology (roundness, smoothness and formation of aggregate and the size 
of nanoparticles formulation were studied by SEM. The solid sample of freeze dried nanoparticle 
were dispersed in water for SEM analysis was coated with a thin layer of platinum or gold using 
the PVD process at a 30MA current from the distance of 50nm during 
Fourier transform infra-red (FTIR) spectroscopy   (Patil S.V., et al., 2009; IP, 2007) 
FTIR study was carried out to check compatibility of drug with polymers. Infrared 
spectrum of Stavudine was determined on Fourier transform Infrared Spectrophotometer using 
KBr dispersion method. The base line correction was done using dried potassium bromide. Then 
the spectrum of dried mixture of drug and potassium bromide was run followed by drug with 
various polymers by using FTIR spectrophotometer. The absorption maximums in spectrum 
obtained with the substance being examined correspond in position and relative intensity to those 
in the reference spectrum represented in Table 8.1 and also shown in Figure 8.1 
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Differential scanning calorimetry (DSC)(Patil S.V., et al., 2009) 
Any possible drug polymer interaction can be studied by thermal analysis. The DSC study was 
performed on pure drug, drug+ Gelatin. The study was carried out using a DSC. The 2 mg of 
sample were heated in a hermetically sealed aluminum pans in the temperature range of 25-300ºc 
at heating rate of 10ºc /min under nitrogen flow of 30ml/min.  
Study of in-vitro releases(vandanasingh .,et al.,2010)  
In vitro release study across cellophane membrane (cut off 3500 Da) precluding gelatin 
was performed in a specially designed diffusion chamber consisting of two compartments 
separated by the membrane. Drug loaded nanoparticles (5 ml equivalent to 8 mg of the drug) 
were placed in the donor compartment and the receptor compartment was filled with 50 ml 
phosphate buffer (pH 6.8). To determine the amount of Rosuvastatin diffused through the 
cellophane membrane, sample (1 ml) was withdrawn from the receiver compartment at the 
prefixed time intervals and the drug concentration was measured spectrophotometrically at 240 
nm. After each withdrawal, same amount of phosphate buffer was replaced in the receiver 
chamberindex. 
7.4. Release kinetics  data (BenoyBrataBhowmik., et al., 2006) 
To study the released kinetics of In-vitro drug release, data was applied to kinetic models 
such as zero order, first order, Higuchi and Korsmeyer- Peppas. 
 Zero order 
 
Where    K0 - is the zero-order rate constant expressed in units of concentration/time   
                 t -is the time in hrs. 
 
C = K0t                                                                                                               
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 First order 
 
Where   C0 - is the initial concentration of drug, 
K - is the first order constant 
t - is the time in hrs.  
 Higuchi 
 
Where   Qt - is the amount of the release drug in time t, 
K- is the kinetic constant and t- is time in hrs 
 KorsmeyerPeppas 
 
Where Mt - represents amount of the released drug at time t,  
M∞- is the overall amount of the drug (whole dose) released after 12 hrs 
          K- is the diffusional characteristic of drug/ polymer system constant  
          n- is a diffusional exponent that characterizes the mechanism of release of drug.  
Table 7.2:Diffusion exponent and solute release mechanism 
Diffusion exponent Overall solute diffusion mechanism 
< 0.5 Quasi-Fickian diffusion 
0.5 Fickian diffusion 
0.5 < n < 1.0 Anomalous (non-Fickian) diffusion 
1.0 Case-II transport 
> 1.0 Super case-II transport 
 
LogC = LogC0 – Kt / 2.303                                                                             
Qt = Kt1/2 
Mt/ M∞ =Kt n                                                                                              
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7.5: Stability studies (Manavalan R. and Ramasamy S., 2004) 
The International Conference on Harmonization (ICH) Guidelines titled “Stability testing 
of New Drug Substances and Products (QIA) describes the stability test requirements for drug 
registration application in the European Union, Japan and the States of America  
ICH specifies the length of study and storage conditions 
Long-Term Testing: 25
0 
C ±2
0 
C at 60% RH ±5% for 12 Months  
Accelerated Testing: 40
0 
C ±2
0 
C at 75% RH ±5% for 6 Months  
In present study the selected formulation F1 was exposed   up to 3 months of stability 
studies at room temperature, accelerated condition and refrigerator temperature (250± 20C at 60% 
RH±5%RH, 400C ±20C at 750% RH ±5% RH and 5
0
C ±3
0
C ) to find out the effect of aging on 
drug loading efficiency. 
Procedure: (KalariaD.R.,et al., 2008:Jospech Nisha  Carry., et al., 2006) 
 Stability studies were carried out by freeze dried nanoparticles as per ICH titled QIA 
guide lines meant for refrigerated product over a period of 90 days. Nanoparticles were kept in 
stability chamber with temperature at 250± 20C at 60% RH±5%RH, 400C ±20C at 75% RH 
±5%RH and 50C ±30C. Sucrose (5%) was used as Cryoprotectant during the freeze drying 
process. Samples were withdrawn predetermined time intervals and analyzed the drug loading 
efficiency. 
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7.6. Zeta potential:(Maincent P., et al 1997)   
The zeta potential value of the sample was measured by zetasizer.A nanoparticle 
formulation which gives best results between particle size, drug loading efficiency, in-vitro drug 
release was determined for zeta potential. Zeta potential it can help to understand the 
characteristics of a suspension by understanding how individual colloids interact with one 
another. Each colloid carries aelectrical charge is high enough, the colloids will remain discrete, 
disperse and in suspension. The report was showed in Figure 8.33. 
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8.RESULTS AND DISCUSSION 
8.1: Preformulation parameters 
 Identification of drug 
Identification by FTIR spectroscopy 
The FTIRspectrum of Rosuvastatin was shown in Figure 8.1 and theinterpretations of 
FTIR frequencies were showed in Table 8.1 
 
 
 
Figure 8.1:FTIR spectrum of Rosuvastatin 
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Table 8.1:Characteristic frequencies in FTIR spectrum of Rosuvastatin 
Wave no.(cm-1) Inference 
1335 So2 stretching 
1068 C-F stretching 
1381 C-N stretching (aromatic amine) 
3035 C-H stretching 
1604 C=C Skeletal stretching (Aromatic) 
2968 C-H stretching 
2872 CH3  symmetric stretching 
3380 C-H stretching 
1728 C=O stretching 
1547 CO2 symmetric stretching 
810 C-S stretching 
 
 Interpretation of FTIR Spectrum 
Major functional groups like Aliphatic Ethers,Aliphatic Hydrocarbons, and Primary Aliphatic 
Alcohols,present in Rosuvastatin showed characteristic peaks in FTIR spectrum. The major 
peaks were identical to functional group of Rosuvastatin. Hence, the sample was confirmed as 
Rosuvastatin 
Melting point 
Melting point values of Rosuvastatin sample was found to be in range of 1550C to 1560C. 
The reported melting point for Rosuvastatin was154.330C. Hence, experimental values were 
fitted with standard values. 
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Solubility study 
Table 8.2:Solubilityprofile of Rosuvastatin calcium in polar and non-polar solvents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From the above data the solubility of Rosuvastatin was confirmed in various polar and 
non polar solvents. 
S. No      SOLVENTS EXTENT OF SOLUBILITY CATEGORY 
1. Distilled water 
10 mg of substance was not 
soluble upto 100 ml of solvent 
Practically insoluble 
2. Methanol 10 mg in 0.31 ml Sparingly soluble 
3. Ethanol 10 mg in 0.36 ml Sparingly soluble 
4. Acetonitrile 10 mg in 0.05 ml Freely soluble 
5. Di-methylFormamide 10 mg in 0.04ml Freely soluble 
6. Acetone 10 mg in 0.02 ml Freely soluble 
7. Glacial acetic acid 10 mg in 0.04 ml Freely Soluble 
8. Cyclohexane 10 mg in 0.3 ml Soluble 
9. Chloroform 10 mg in 0.01 ml Freely soluble 
10. Petroleum ether 10 mg in 0.45 ml Sparingly soluble 
11. n- Butanol 10 mg in 0.07 ml Freely soluble 
12 Carbon tetra chloride 10 mg in 0.04 ml Freely soluble 
13 Benzene 10 mg in 0.09 ml Freely insoluble 
15 Iso propyl alcohol 10 mg in 0.55 ml Sparingly soluble 
16 Hexane 10 mg in 0.29 ml Soluble 
17 Diethyl ether 10 mg in 0.09 ml Freely soluble 
18 Dichloro methane 10 mg in 0.02 ml Freely soluble 
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Physicochemical parameters of drug 
Organoleptic properties 
Odour:Odourless 
Colour:  White or almost white  
Nature: Crystalline powder. 
Loss on drying 
The percentage loss on drying after 3 hours was found to be as follows 
Table 8.3:  Percentage loss on drying for Rosuvastatin 
 
 
 
 
 
 
The sample passes test for loss on drying as per the limit specified in IP, 2007 (N.M.T. 1%).It 
was shown in Table 8.3 
 
 
 
 
 
 
 
 
 
 
 
 
S. No Percentage  LOD Avg. percentage LOD 
1 0.7  
0.5666±0.25 
 
2 0.4 
3 0.8 
Gelatin Loaded Rosuvastatin Nanoparticles                                               Results and Discussion 
 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 84 
 
Analytical methods 
Determination of λ max in 0.1N methanol: 
The absorption maximum for Rosuvastatin in 0.1N Methanol was found to be 244 nm 
and   absorption maximum was shown in Figure 8.2. 
 
Figure 8.2:  λ max observed for Rosuvastatin in 0.1N Methanol 
 
Preparation of standard graph of Rosuvastatin in 0.1N methanol 
 
Absorbance obtained for various concentrations of Rosuvastatinin 0.1N Methanol were 
given in Table.8.4.and Figure 8.3.The graph of absorbance vs concentration for Rosuvastatin was 
found to be linear in the concentration range of 10 μg /ml. The calibration curve parameters 
shown in Table.8.5So the drug obeys Beer- Lambert’s law in the range of 10 μg /ml. 
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Table 8.4:Data of concentration and absorbance for Rosuvastatin in 0.1N Methanol 
 
S.NO Concentration 
(µg/ml) 
 
Absorbance 
at 244nm 
1 0 0 
2 1 0.062 
3 2 0.122 
4 3 0.183 
5 4 0.245 
6 5 0.308 
7 6 0.371 
 
 
Figure 8.3: Calibration curve of Rosuvastatin calcium in methanol at 244 nm  
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         Table 8.5:Data for calibration curve Parameters for 0.1 methanol 
 
S.NO PARAMETERS VALUES 
1 Correlation coefficient (r2) 0.99996 
2 Slope (m) 0.06171 
3 Intercept(c)   -0.00071 
 
Determination of λ max in 6.8 phosphate buffer: 
The absorption maximum for Rosuvastatin in 6.8 phosphate buffer was found to be  
240 nm and   absorption maximum was shown in Figure 8.4 
 
 
Figure 8.4:  λ max observed for Rosuvastatin in 6.8 buffer 
Preparation of standard graph of Rosuvastatin in 6.8 phosphate buffer: 
Absorbance obtained for various concentrations of Rosuvastatin in6.8 phosphate buffer  
were given in Table8.6.and Figure 8.6 .The graph of absorbance vs concentration for 
Rosuvastatin was found to be linear in the concentration range of 10 μg /ml.The calibration curve 
parameters shown in Table 8.7.So the drug obeys Beer- Lambert’s law in the range of 10 μg /ml. 
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Table  8.6: Calibration curve of Rosuvastatin calcium in 6.8 phosphate buffer at 240 nm  
S.NO Concentration (µg/ml) 
 
Absorbance 
at 240nm 
1 0 0 
2 1 0.071 
3 2 0.142 
4 3 0.211 
5 4 0.278 
6 5 0.349 
7 6 0.423 
 
 
 
Figure 8.5:Calibration curveofRosuvastatin calcium in 6.8 buffer at 240 nm 
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Table 8.7:Data for calibration curve Parameters for in 6.8 phosphate buffer 
S.NO Parameters Values 
1 Correlation coefficient (r2) 0.999936 
2 Slope (m) 0.0070036 
3 Intercept ( c )  -0.000464 
 
Percentage purity of drug 
The percentage purity of drug was calculated by using calibration graph method (least 
square method). 
Table 8.8:  Percentage purity of drug 
  
 
 
 
 
 
 
All the values are expressed as mean± S.D., n=3. 
The reported percentage purity for Rosuvastatin in IP 2007 is 98 to 99.53%. 
 
 
 
 
 
 
 
 
 
S. No Percentage purity (%) Average percentage 
purity (%) 
1 99.10  
99.07±1.24 2 99.53 
3 99.60 
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Determination of compatibility for drug with polymer 
 
By FTIR spectroscopy 
 
 
Figure 8.6:FTIR spectrum of  Rosuvastatin 
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Figure  8.7: FTIR spectrum of drug and gelatin A. 
 
 
Figure 8.8:FTIR spectrum of drug and gelatin B. 
 
Gelatin Loaded Rosuvastatin Nanoparticles                                               Results and Discussion 
 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 91 
 
 
Interpretation of FTIR spectrum: 
Table 8.9:Interpretation of FTIR spectrum 
S.NO FORMULATION 
WAVE NUMBER 
(CM-1) 
1. 
Pure Rosuvastatin 
3380.24,3055.78,2968.01,2931.92,2872.22,2575.59,1898.99 
1604.08,1547.88,1509.57,1437.50,1381.61,1335.16,1229.07,1197.11, 
1154.53,1121.04,1068.49,1014.21,964.91,900.92,844.55,810.59,776.11, 
714.58 
2. 
Gelatin 
2959.12,2926.12,2855.03,2644.11,2400.33,2140.11,1981.23,1731.97,168
5.40,1630.59,1562.14,1510.10,1451.12,1406.01,1326.57,1245.14,1192.35
,1156.55,1180.31,1022.55,970.48,918.44,871.87,773.26,721.22,668.20 
3. 
Rosuvastatin+ 
Gelatin 
3378.20,2968.34,2934.43,2872.44,2572.85,2501.63,2438.62,2095.31,190
7.21,1608.63,1554.73,1444.27,1380.42,1334.82,1229.07,1197.20,1154.08
,111.30,1068.58,1014.82,965.00,900.91,810.68,844.62,776.15,714.62 
 
 According to Table 8.9 and Figure 8.6 to 8.8.The major peaks observed in drug spectrum  
also observed in drug with polymerspectrum.ThereforeFTIR spectrums were compared; it could 
indicate that there was no incompatibility between drug and polymer. 
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By DSC thermal analysis 
The compatibility and interactions between drugs and polymer were analysed  
byDSCthermogram and results  were obtained represented and shown in Figure 8.9 to 8.11. 
 
Figure 8.9: DSC thermo grams of Rosuvastatin 
 
Figure 8.10:DSC thermo grams of  Rosuvastatin+ gelatin A 
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Figure 8.11:DSC thermo grams of  Rosuvastatin+ gelatin B 
 
The possible drug and polymer interaction can be studied  by using DSC. The Rosuvastatin 
exhibits a sharp endometric peak 155.8 which is corresponding with its melting point at figure 
8.10 and the Rosuvastatin + gelatin A and B exhibits the sharp endometric peak 155.5 at figure 
8.9. Therefore  when compared with pure drug thermo gram. No interaction was found between 
drug and polymers.  
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8.2. Characterization of nanoparticles 
 Drug loading efficiency (%le) and drug loading capacity (%LC): 
The results were shown in Table 8.10 and Figure.8.12 to 8.13. It is revealed that the highest, 
%LE and %LC in the nanoparticle preparation were obtained. 
Table 8.10: % LE and % LC of Rosuvastatin  nanoparticles with gelatin A and gelatin B 
S.NO  
Parameter 
Formulation (Gelatin A) Formulation (Gelatin B)  
F1 F2 F3 F4 F5 F6 F7 F8 
1 Drug entrapment 
efficiency (LE %) 
91.73 72.93 76.50 86.27 69.85 87.74 88.68 68.72 
2 Drug loading 
capacity (Lc %) 
66.21 55.62 49.41 39.54 65.22 54.14 61.33 47.54 
 
 
 
Figure 8.12:% LE and % LC of  Rosuvastatin  nanoparticles with gelatin A 
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Figure 8.13:% LE and % LC of  Rosuvastatin  nanoparticles with gelatin B 
 
Morphological characterization of F1 to F4 (gelatin A) 
Rosuvastatin loaded polymeric nanoparticles were fabricated usingin-situ two step 
desolvationmethodusing polymer Gelatin A. 
 The choice of an in-situ two step desolvation method of encapsulation was usually 
determined by the %yield, LE and %LC of the drug and sonication process which allowed 
reducing considerably the mean particle size and simultaneously to narrow the width of the size 
distribution, i.e. reduces the polydispersity index. The effectiveness of in-situ two step 
desolvation  method   and polymer on nanoparticle preparation was confirmed by their size, in-
vitro release characteristics. 
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Morphological characterization of F5to F8 (gelatin B) 
Rosuvastatin loaded polymeric nanoparticles were fabricated usingin-situ two step 
desolvation method   using polymer Gelatin B. 
The choice of a  of  two step desolvation method encapsulation was usually determined by the 
solubility characteristics of the drug and high pressure homogenization process which allowed 
reducing considerably the mean particle size and simultaneously to narrow the width of the size 
distribution, i.e. reduced the polydispersity index. The effectiveness of two step 
desolvationmethod and polymer, on nanoparticle preparation was confirmed by their size,in-vitro 
release characteristics.  
 
Figure 8.14:Scanning electron microscopy image of F1 
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Figure 8.15: Particle size distribution F1 
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In-vitro Drug Release profile 
 In-vitro drugreleased profiles of Rosuvastatin nanoparticles were performed in each 
formulation dipped in the phosphate buffer (6.8 pH) upto  16 hours. It was represented in Table 
8.11 and showed in Figure 8.16 to 8.24. 
Table 8.11 Percentage in vitro drug released of Formulations F1-F8 
S.
No 
Ti
me 
in 
hou
rs 
pH 
medi
um 
Gelatin A 
Percentage drug released(%) 
Gelatin B 
Percentage drug released (%) 
F1 
% 
F2 
% 
F3 
% 
F4 
% 
F5 
% 
F6 
% 
F7 
% 
F8 
% 
1 2 
6.
8 
ph
os
ph
at
e 
bu
ff
er
 
11.49±
0.11 
12.83±
0.32 
9.26±0.
37 
10.60±
0.52 
9.71±0.
65 
7.48±1.
87 
8.37±0.
25 
13.50±
0.89 
2 4 21.76±
0.22 
20.86±
0.23 
16.8±0.
25 
16.62±
0.35 
19.30±
0.44 
15.95±
0,21 
17.29±
0.87 
22.87±
1.25 
3 6 33.13±
0.52 
32.46±
0.36 
30.9±1.
25 
30.01±
0.54 
31.35±
0.87 
28.45±
0.78 
29.34±
0.54 
31.39±
1.22 
4 8 48.30±
0.17 
43.84±
0.21 
44.07±
0.36 
44.96±
0.58 
47.63±
1.58 
45.85±
0.25 
46.03±
0.77 
45.40±
0.57 
5 10 63.47±
0.33 
61.02±
0.87 
62.81±
0.14 
61.98±
1.25 
64.14±
0.47 
62.14±
0.74 
63.44±
0.52 
63.92±
0.11 
6 12 79.76±
0.54 
78.20±
1.22 
75.97±
0.87 
74.41±
1.74 
77.31±
1.87 
76.41±
1.25 
75.08±
1.58 
75.97±
1.87 
7 14 87.87±
0.58 
85.56±
1.25 
79.09±
0.65 
81.99±
0.98 
85.78±
1.22 
84.89±
0.78 
83.11±
1.32 
82.66±
0.85 
8 16 93.38±
1.20 
92.25±
0.44 
88.24±
1.47 
84.89±
0.14 
92.49±
0.57 
91.59±
0.87 
87.35±
0.58 
86.68±
0.74 
All the values were expressed as mean ± SD., n=6 
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Figure 8.16:Graphical representation of invitro percentage drug released for formulation F1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.17:Graphical representation of invitro percentage drug released for formulation F2 
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Figure8.18: Graphical representation of invitro percentage drug released for formulation F3 
 
 
 
 
Figure8.19:Graphical representation of invitro percentage drug released forformulation F4 
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Figure 8.20:Graphical representation of invitro percentage drug released for formulation F5 
 
 
 
 
Figure 8.21:Graphical representation of invitro percentage drug released for formulation F6 
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Figure 8.22: Graphical representation of invitro percentage drug released for formulation F7 
 
 
 
 
 
Figure 8.23:Graphical representation of invitro percentage drug released for formulation F8 
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Figure 8.24: Graphical representation of comprehensive invitro percentage drug released for 
formulations F1-F8 
  
Release Kinetics of In-vitro Drug Release 
                The kinetics of in-vitro drug released was determined by applying the drug release data 
to various kinetic models such as zero order first order, Higuchi and Korsmeyer- Peppas. The 
results obtained were represented Table 8.12 and Figure 8.25 to 8.32. 
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Table 8.12: Release kinetics of In-vitro drugrelease gelatin A and gelatin B 
Formulations Zero order 
R2 
First order 
R2 
Higuch 
R2 
Peppas 
R2 
Best Fit 
Model 
F1 0.991 0.845 0.978 0.837 Zero 
F2 0.986 0.873 0.974 0.734 Zero 
F3 0.983 0.914 0.975 0.924 Zero 
F4 0.981 0.923 0.968 0.864 Zero 
F5 0.992 0.838 0.976 0.877 Zero 
F6 0.989 0.870 0.964 0.962 Zero 
F7 0.983 0.907 0.973 0.821 Zero 
F8 0.984 0.929 0.968 0.912 Zero 
 
 
 
 
 
Figure 8.25:Best fit model (zero order) of formulation F1 
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Figure 8.26:Best fit model (zero order) of formulation F2 
 
 
 
Figure 8.27Best fit model (zero order) of formulation F3 
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Figure 8.28:Best fit model (zero order) of formulation F4 
 
 
Figure 8.29:Best fit model (zero order) of formulationF5 
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Figure 8.30:Best fit model (zero order) of formulation F6 
 
 
 
Figure 8.31:Best fit model (zero order) of formulation F7 
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Figure 8.32:Best fit model (zero order) of formulation F8 
From the data and graphical representations, the Rosuvastatin nanoparticles formulations 
were showed well fitted zero order kinetics and formulation F1 was showed best among the 
formulations were prepared based on morphology, %drug loading efficiency, in-vitro drug 
released profiles and also well fitted the zero order kinetics. 
8.3 Stability studies 
      FormulationF1was kept in room temperature, accelerated condition and refrigerator 
temperature. After exposed to specified periods of time the samples were analyzed for %LE.  
Results were represented in Table 8.13 
 
 
 
 
 
 
 
R² = 0.984
0
20
40
60
80
100
0 2 4 6 8 10 12 14 16 18
%
 D
ru
g 
re
le
as
ed
Time in hours
Gelatin Loaded Rosuvastatin Nanoparticles                                               Results and Discussion 
 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 109 
 
Table 8.13:Stability studies of optimized formulation (F1). 
 
S.No 
 
Temperature(00c) 
Drug loading efficiency(%LE) 
   1st month 2nd month 3rd month 
1 250C±20C at RH 60%±5%          98.45 98.98 97.93 
2 400C±20C at RH 75%±5%          98.55 96.80 96.92 
3 50C±30C          98.29 98.14 97.35 
 
No major difference was found between %LE before and after stability studies.The 
formulation F1 was showed satisfactory physical stability at 250C ±20C at RH 60%±5%, 400C 
±20C at RH 75%±5% and 50C±30C. 
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8.4. Zeta potential 
 The zeta potential report of the formulation F1 showed in Figure 8.33. The obtained value 
was the positive value. 
                           
Figure 8.33: Zeta potential of F1 formulation 
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                The Rosuvastatin was widely used  in the antilipedimic drug.This research work 
mainly focused on therapeutic effect of the drug to increased Bioavailability. The reported 
Bioavailability of Rosuvastatin was only 20%. While forming the novel drug delivery system  in 
the form of nanoparticle to increased the bioavalability. 
   Eight formulations were prepared by using drug with gelatin A and gelatin B in 
different  ratio of 1:1,1:2,1:3 and1:4 each polymer respectively(F1 to F8). Among the eight 
formulations F1 formulation was best because of these formulation shows the optimized result of 
colloidal drug delivery systems of nanoparticles have emerged as an efficient means enhancing 
the bioavailability with lowest possible dose. 
              The present work was proposed to prepared nanoparticles loaded with Rosuvastatin to 
achieved better bioavailability with low dose of the drug at the site, decreased the risk of adverse 
side effects. Rosuvastatin  nanoparticles were prepared by in-situ  two step desolvation method.   
             The loading efficiency(F1) and Entrapment efficiency(F1)  was  66.21 and  91.73 
respectively.  
             The shape of nanoparticle was found to be spherical by SEM analysis. Formulation with 
high polymer content was observed to be fairly spherical. Compatability of drug and polymer 
mixture was done by performing FTIR and DSC study. It was concluded that there was no 
interaction between drug and polymer. 
              9. SUMMARY AND CONCLUSION 
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                 The in-vitro released of Rosuvastatin was evaluated in phosphate buffer saline (pH6.8) 
up to 16hrs. The formulation F1 was released the drug 93.38% up to16 hours. and chosen the 
best among the formulations were prepared.  
                 Zeta potential was determined for the formulation F1 and it was found to be +ve value 
of 1.57mv. 
     The in-vitro drug released data was applied to various kinetic models like zero order 
kinetics, Higuchi plot, first order kinetics, and Peppas plot by predict the drug release kinetics 
mechanism. The formulation F1 was best fitted the zero order kinetics.  
      In short term  stability studies the formulation F1 was showed that there was no 
remarkable changes in the % drug loading efficiency. 
                  Based on the % drug loading efficiency, zeta potential, in-vitro drug release profile, 
in-vitro drug release kinetics and stability studies the formulation F1 was found to be best one 
among the formulations (F1 to F8)   were prepared. 
       These nanoparticles can be promising agents for rational drug delivery in lipidemic 
condition. 
  
 
  
 
Future prospects 
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1. Nano-drug delivery systems that deliver large but highly localized quantities of drugs to 
specific areas to be released in controlled ways. 
2. Controllable release profiles, especially for sensitive drugs. 
3. Materials for nanoparticles that are biocompatible and biodegradable. 
4. Architectures / structures, such as biomimetic polymers, nanotubes. 
5. Technologies for self-assembly. 
6. Advanced polymeric carriers for the delivery of therapeutic peptide/proteins 
(biopharmaceutics). 
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